    
CLINICAL STUDY PROTOCOL
Study Title: A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 
3 Study to Assess the E fficacy and Safety of Filgotinib Administered 
for 24 weeks in C ombination with Conventional Synthetic
Disease-modifying Anti-rheumatic Drug(s
)(csDMARDs) to Subjects 
with Moderatelyto Severely Active Rheumatoid Arthritis W ho Have 
an Inadequate Response to B iologic DMARD (s)Treatment
Sponsor: Gilead Sciences, Inc.
333 Lakeside Drive
Foster City , CA 94404
USA
IND Number:
EudraCT Number :
Clinical Trials.gov 
Identifier :115,510
2016-000569-21
TBD
Indication: Rheumatoid Arthritis 
Protocol ID: GS-US-417-0302
Gilead 
Clinical 
Program Manager :Name: Rebecca Py le
Telephone:
Gilead Medical 
Monitor:Name: Franziska Matzkies
Telephone:
Fax:
Pager:
Protocol Version/Date: Original: 22April2016
Amendment 1: 05July2016
CONFIDENTIALITY STAT EMENT
The information contained in this document, particularly unpublished data, is the propert y or 
under control of Gilead Sciences, Inc., and is provided to you in confidence as an investigator, 
potential investigator, or consultant, for review b y you, your staff, and an applicable Institutional 
Review Board or Independent Ethics Committee. The information is only  to be used by  you in 
connection with authorized clinical studies of the investigational dru g described in the protocol. 
You will not disclose any of the information to others without written authorization from 
GileadSciences, Inc., except to the extent necessary  to obtain informed consent from those 
persons to whom the drug may  be administered.
PPD
PPD
PPD
PPD
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page2 05July2016TABLE OF CONTENTS
TABLE OF CONTENTS .............................................................................................................................................. 2
LIST OF IN- TEXT TABLES ........................................................................................................................................ 5
PROTOCOL SYNOPSIS ................................
.............................................................................................................. 6
GLOSSARY OF ABBREVIA TIONS AND DEFINITION OF TERMS .................................................................... 14
1.INTRODUCTION .............................................................................................................................................. 17
1.1.Background ............................................................................................................................................ 17
1.2.Filgotinib ................................................................................................................................................ 18
1.2.1. General Information ............................................................................................................. 18
1.2.2. Nonclinical Pharmacology, Absorption, Distribution, Metabolism, and 
Excretion (ADME) and Toxicology ..................................................................................... 18
1.2.3. Clinical Tri als of Filgotinib .................................................................................................. 20
1.3.Rationale for This Study ........................................................................................................................ 25
1.3.1. Rationale for Study Design .................................................................................................. 25
1.3.2. Rationale for the Outcome Measures ................................................................................... 26
1.3.3. Rationale for the Choice of Dose and Dosing Interval ......................................................... 27
1.4.Risk/Benefit Assessment for the Study .................................................................................................. 28
1.5.Compliance............................................................................................................................................ 29
2.OBJECTIVES ..................................................................................................................................................... 30
3.STUDY DESIGN ................................................................
................................................................................ 31
3.1.Endpoints ............................................................................................................................................... 31
3.2.Study Design .......................................................................................................................................... 32
3.3.Study Treatments................................................................................................................................... 33
3.4.Duration of Treatment ............................................................................................................................ 33
3.5.Criteria for Interruption or Discontinuation of Study Treatment ........................................................... 34
3.5.1. Study Drug Interruption Considerations ............................................................................... 34
3.5.2. Study Drug Discontinuation Considerations ........................................................................ 34
3.6.End of Study ..............................................................................................................................
.............36
3.7.Post Study Care ...................................................................................................................................... 36
3.8.Biomarker Samples ................................................................................................................................ 36
3.8.1. Biomarker Samples to Address the Study Objectives .......................................................... 36
3.8.2. Biomarker Samples for Optional Future Research ............................................................... 37
3.8.3. Biomarker Samples for Optional Genomic Research ........................................................... 38
3.9.SUBSTUDY: .39
4.SUBJECT POPULATION .................................................................................................................................. 40
4.1.Number of Subjects and Subject Selection ............................................................................................ 40
4.2.Inclusion Criteria ...............................................................
..................................................................... 40
4.3.Exclusion Criteria ................................................................................................................................... 42
5.INVESTIGATIONAL MEDI CINAL PRODUCTS........................................................................................... 46
5.1.Randomization, Blinding and Treatment Codes .................................................................................... 46
5.1.1. Procedures for Breaking Treatment Codes ........................................................................... 46
5.2.Description and Handling of Filgotinib and PTM Filgotinib ................................................................. 46
5.2.1. Formulation of Filgotinib and PTM Filgotinib ..................................................................... 46
5.2.2. Packaging and Labeling ....................................................................................................... 47
5.2.3. Storage and Handling ........................................................................................................... 47
5.2.4. Dosage and Administration .................................................................................................. 47
5.3.Prior and Concomitant Medications ....................................................................................................... 48
PPD
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page3 05July20165.4.Accountability for Study Drugs ............................................................................................................. 50
5.4.1. Investigational Medicinal Product Return or Disposal ......................................................... 51
6.STUDY PROCEDURES .................................................................................................................................... 52
6.1.Subject Enrollment and Treatment Assignment ..................................................................................... 52
6.2.Pretreatment Assessments ...................................................................................................................... 52
6.2.1. Screening Visit ..................................................................................................................... 52
6.2.2. Day 1 Assessments ............................................................................................................... 54
6.3.Randomization ....................................................................................................................................... 55
6.4.Week 2 through Week 20 Assessments ................................................................................................. 55
6.5.Week 24/Early Termination ...............................................................
.................................................... 56
6.6.Post-treatment Week 4 Assessments ...................................................................................................... 58
6.7.Study Assessments ................................................................................................................................. 58
6.7.1. Efficacy................................................................................................................................ 58
6.7.2. Safety and Tolerability ......................................................................................................... 62
6.7.3. Clinical Laboratory Evaluations ........................................................................................... 62
6.7.4. Vital Signs ............................................................................................................................ 62
6.7.5. Physical Examination ........................................................................................................... 63
6.7.6. Other Safety Assessments .................................................................................................... 63
6.8.Pharmacokinetics Assessments .............................................................................................................. 63
6.9.Biomarker Assessments ......................................................................................................................... 63
7.ADVERSE EVENTS AND T OXICITY MANAGEMENT ............................................................................... 64
7.1.Definitions of Adverse Events, Adverse Reactions, and Serious A
dverse Events ................................. 64
7.1.1. Adverse Events ...............................................................
...................................................... 64
7.1.2. Serious Adverse Events ........................................................................................................ 64
7.1.3. Clinical Lab oratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events ......................................................................... 65
7.2.Assessment of Adverse Events and Serious Adverse Events ................................................................. 65
7.2.1. Assessment of Causality for Study Drugs and Procedures ................................................... 65
7.2.2. Assessment of Severity ................................
........................................................................ 66
7.3.Investigator Requirements and Instructions for Reporting Advers
e Events and Serious 
Adverse Events to Gilead ....................................................................................................................... 66
7.4.Gilead Reporting Requirements ............................................................................................................. 68
7.5.Clinical Laboratory Abnormalities and Other Abnormal Assessments as Adverse Events or 
Serious Adverse Events .......................................................................................................................... 68
7.5.1. Grades 1 and 2 Laboratory Abnormality or Clinical Event .................................................. 69
7.5.2. Grades 3 Laboratory Abnormality or Clinical Event ........................................................... 69
7.5.3. Grades 4 Laboratory Abnormality or Clinical Event ........................................................... 69
7.6.Toxicity Management ............................................................................................................................ 70
7.7.Special Situations Reports ...............................................................
....................................................... 70
7.7.1. Definitions of Special Situations .......................................................................................... 70
7.7.2. Instructions for Reporting Special Situations ....................................................................... 71
8.STATISTICAL CONSIDER ATIONS................................................................................................................ 73
8.1.Analysis Objectives and Endpoints ........................................................................................................ 73
8.1.1. Analysis Objectives .............................................................................................................. 73
8.1.2. Primary Endpoint ................................................................................................................. 73
8.1.3. Secondary Endpoints ............................................................................................................ 74
8.2.Analysis Conventions ............................................................................................................................. 75
8.2.1. Analysis Sets ........................................................................................................................ 75
8.3.Data Handling Conventions ................................................................................................................... 75
8.4.Demographic Data and Baseline Characteristics ................................................................................... 76
8.5.Efficacy Analysis ................................................................................................................................... 76
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page4 05July20168.5.1. Primary Analysis .................................................................................................................. 76
8.5.2. Secondary Analyses ............................................................................................................. 76
8.6.Safety Analysis ....................................................................................................................................... 77
8.6.1. Extent of Exposure ............................................................................................................... 77
8.6.2. Adverse Events ..................................................................................................................... 77
8.6.3. Laboratory Evaluations ........................................................................................................ 78
8.7.Pharmacokinetic Analysis ...................................................................................................................... 78
8.8.Biomarker Analysis ................................................................................................................................ 78
8.9.Sample Size................................
................................................................
............................................ 78
8.10.Data Monitoring Committee .................................................................................................................. 79
8.11.Cardiovascular Endpoint Adjudication Committee ................................................................................ 79
9.RESPONSIBILITIES .......................................................................................................................................... 80
9.1.Investigator Responsibilities .................................................................................................................. 80
9.1.1. Good Clinical Practice .......................................................................................................... 80
9.1.2. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Review and Approval ........................................................................................................... 80
9.1.3. Informed Consent ................................................................................................................. 80
9.1.4. Confidentiality ...................................................................................................................... 81
9.1.5. Study Files and Retention of Records .................................................................................. 81
9.1.6. Case Report Forms ............................................................................................................... 82
9.1.7. Investigational Medicinal Product Accountability and Return ............................................. 83
9.1.8. Inspections ................................
............................................................................................ 83
9.1.9. Protocol Compliance ............................................................................................................ 83
9.2.Sponsor Responsibilities ........................................................................................................................ 84
9.2.1. Protocol Modifications ......................................................................................................... 84
9.2.2. Study Report and Publications ............................................................................................. 84
9.3.Joint Investigator/Sponsor Responsibilities ........................................................................................... 84
9.3.1. Payment Reporting ............................................................................................................... 84
9.3.2. Access to Information for Monitoring .................................................................................. 85
9.3.3. Access to Information for Auditing or Inspections .............................................................. 85
9.3.4. Study Discontinuation .......................................................................................................... 85
10.REFERENCES ................................................................................................................................................... 86
11.APPENDICES .................................................................................................................................................... 88
Appendix 1.Investigator Signature Page .................................................................................................... 89
Appendix 2.Study Procedures Table .......................................................................................................... 90
Appendix 3.Management of Clinical and Laboratory Adverse Events ...................................................... 95
Appendix 4.Common Terminology Criteria for Adverse E vents (CTCAE) v4.03 .................................... 96
Appendix 5.Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Methods ........................................................................................................... 97
Appendix 6.Laboratory Assessment Table .............................................................................................. 101
Appendix 7.List of Joints to be Evaluated (66/68 Joint Count) ............................................................... 102
Appendix 8.The 2010 American College of Rheumatology –European League Against 
Rheumatism Collaborative Initiative Classifica tion Criteria for Rheumatoid 
Arthritis {Aletaha et al 2010} ,.............................................................................................. 103
Appendix 9.American College of Rheumatology Response Evaluations/ Preliminary Definition 
of Improvement in Rheumatoid Arthritis {Felson et al 1995} ............................................. 105
Appendix 10.Disease Activity Score (DAS28) {Prevoo et al 1995} ......................................................... 107
Appendix 11.Procedures and Specifications .............................................................................................. 108
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page5 05July2016LIST OF IN -TEXT TABLES
Table1-1. Summary and analysis of ACR20/50/70 response at Weeks 12 and 24 (NRI [ITT 
Population]), GLPG0634 -CL-203.......................................................................................... 21
Table1-2. Summary and analysis of ACR20/50/70 response at Weeks 12 and 24 (NRI [ITT 
Population]); GLPG0634 -0204.............................................................................................. 24
Table7-1. Grading of Adverse Event Severity ........................................................................................ 66
LIST OF IN -TEXT FIGURES
Figure3-1.Study Design .......................................................................................................................... 33
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page6 05July2016PROTOCOL SYNOPSIS
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
USA
StudyTitle: A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 
3 Study to Assess the E fficacy and Safety of Filgotinib Administered 
for 24 weeks in C ombination with Conventional Synthetic 
Disease-modifying Anti-rheumatic Drug(s
)(csDMARDs) to Subjects 
with Moderatelyto Severely Active Rheumatoid Arthritis Who H ave 
an Inadequate Response to B iologic DMARD (s)Treatment
IND Number:
EudraCT Number:
Clinical Trials.gov 
Identifier:115510
2016-000569-21
TBD
Study Centers 
Planned:Approximately  80-120centers worldwide
Objectives: The primary  objective of this study  is:
To evaluate the effects of filgotinib versus placebo for the 
treatment of signs and s ymptoms of rheumatoid arthritis (RA)as 
measured b y the proportion of subjects achieving an American 
College of Rheumatology 20% improvement response (ACR20) at 
Week12 
The secondary  objectives of this study  are: 
To evaluate the effects of filgotinib versus placebo for the 
treatment of signs and s ymptoms of RA as measured by the 
proportion of subjects achieving Disease Activity  Score for 
28joint count using c-reactive protein (DAS28[CRP])≤3.2at 
Week 12
To evaluate the effect of filgotinib versus placebo on physical 
function as measured b y change from Baselineinthe Health 
Assessment Questionaire Disability  Index(HAQ-DI)at Week 12
To evaluate the safet y and tolerability  of filgotinib
To evaluate the effects of filgotinib on work producti vity, fatigue, 
and general quality  of lifeas measured b y SF-36, FACIT -Fatigue,
EQ-5Dand WPAI -RA
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page7 05July2016The exploratory  objective of this study  is as follows: 
 
 
 
Study Design: This is a randomized, double -blind, placebo -controlled ,add-on,
Phase3study in adult male and female subjects with active RA 
despite csDMARD (s
)therapy (ie, MTX, hydroxychloroquine, 
sulfasalazine, leflunomide) who have had an inadequate response or 
are intolerant to at least one biologic DMARD (bDMARD) . 
Approximately  423subjects will be randomized in a 1:1:1 ratio to 
filgotinib 200 mg, filgotinib 100 mg, or placebo to match (PTM) 
administered for up to 24 weeks, all in the context of a stable dose of 
permitted csDMARD(s):
Filgotinib 200 mg group: filgotinib (200 mg once daily[q.d.]
)+  
PTMfilgotinib 100 mg (PTM q.d.) ( N=141) 
Filgotinib 100 mg group: filgotinib (100 mg q.d.)+ PTM filgotinib 
200 mg (PTM q.d.) (N=141)
Placebocontrolgroup: PTMfilgotinib 200 mg 
(PTM q.d.) and 
PTMfilgotinib 100 mg (PTM q.d.) (N=141) 
Randomization will be stratified b ygeographic region,prior exposure 
to number of bDMARDs (<3 or >=3 bDMARDs) and presence of
rheumatoid factor (RF) oranti-CCP(cyclic citrullinated peptide)
antibody (Ab))at screening .
At Week 14, subjects who have not achieved at least 20% 
improvement from Day  1 in both swollen joint count (SJC) and tender 
joint count (TJC) will discontinue investigational study drug 
dosing
but will continue with study  visits and assessments per protocol. A ll 
subjects meeting this criterion who discontinue from investigational 
therapy are toreceive standard of care treatment for their RA as 
determined b y the investigator. 
All subjects who attain responder status at Week 14 will continue on 
their assigned study  drug, in a blinded fashion through Week 24. 
Placebo-responders at Week 14 will continue on placebo in a blinded 
fashion through Week 24.
PPD
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page8 05July2016All subjects who have received at least one dose of study  drug and exit 
the study early will complete an earl y termination (ET) visit at the 
time of study  discontinuation, with a follow up visit four weeks after 
the last dose of study  drug (Post Treatment visit Week 4), regardless 
of dosing duration.
At completion of the 24 -week dosingperiod all subjects, regardless of 
response, who have not discontinued the study  due to toxicity , will be 
provided the option to enroll into a separate Long TermExtension 
(LTE) study (GS-US-417-0304).
Study Design
Number of Subjects 
Planned:Approximately  423subjects 
Target Population: Male or female subjects  ≥18 years of age with a diagnosis of  RA 
meeting the 2010 ACR/ European League Against Rheumatism
(EULAR)criteria,who have active RA despite treatment with 
csDMARD (s) and have failed or are intolerant to at least one 
bDMARD
Duration of 
Treatment:Up to 24 w eeks 
Diagnosis and Main 
Eligibility  Criteria:For a complete list of study  inclusion and exclusion criteria, please 
refer to Sections 4.2and 4.3.

Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page9 05July2016Main Eligibility  Criteria
1)Male or female subjects who are ≥18 years of age, on the day  of 
signing informed consent.  
2)Have a diagnosis of RA (2010 ACR/EUL AR criteria for RA), and 
are ACR functional class I -III.
3)Have ≥6 swollen joints (from a SJC66) and ≥6 tender joints 
(froma TJC68) at Screening and Day  1
4)Have serum CRP ≥ 4 mg/L  based on central laboratory  analysis at 
Screening
5)Ongoing treatment with a stable prescription of 1 or
2csDMARD (s)as follows: 
Permitted csDMARD s
a)Use of MTX for at least 12 weeks prior to Day  1. Subject is on 
a stably prescribed doseand route of administration of 7.5-
25mg/weekly  for at least 4 weeks prior to Day  1. Stable 
weekly doses < 7.5 mg are allowed onl y in the presence of 
intolerance to or toxicity  from higher doses or where higher 
doses 
are prohibited by  the local label or local clinical 
practice. Doses >25 mg weekl y are not permitted. 
b) Subjects on MTX should be receiving an adequate and stable 
dose of folic acid (≥5 mg/week total dose or as per local 
clinical practice) which should be confirmed or initiated at 
Screening, and continued throughout the study . 
MTX is not permitted to be used in combination with leflunomide.
c)Oral hydroxychloroquine ≤400 mg/day  or chloroquine 
≤250mg/day with prescription having been stable for at least 
4weeks prior to Day  1
d)Oral sulfasalazine 1 g to 3 g/day  with prescription having been 
stable for at least 4 
weeks prior to Day  1
e)Oral leflunomide 10 -20mg/day,with prescription having been 
stable for at least 4 weeks prior to Day  1  
The treatment with csDMARD shouldbe continued at a stable dose 
until the end of the study . Dose adjustments are only  permitted for 
the management of toxicity .Prior treatment with additional 
csDMARDs is allowed, however , subject may  only be on 1 or 
2csDMARDs at Day 1 and appropriate wash out needs to be 
satisfied according protocol (Section 5.3), in order to be eligible for 
the study.
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page10 05July20166)Have received at least one bDMARD for the treatment of RA to 
which they  have had an inadequate response or intolerance. An 
inadequate response is defined as documented continued or 
recurrent disease activity after at least 12 weeks of treatment with 
any investigational or licens ed bDMARD, including biosimilars, 
for the treatment of  RA. Intolerance is defined as treatment 
discontinuation due to any documented adverse effect associated 
with a bDMARD used according to its respective label. There is 
no limit to the prior number of b DMARDs that may  have been 
used by the subject, however the subject may  not be on a 
bDMARD at Day  1 or during the stud y.
Study Procedures/
Frequency :Participating subjects will visit the clinical study  center at Screening , 
Day1, Weeks 2, 4, 8, 12, 14, 16, 20, and Week 24 or at ET.
For those subjects not entering the LTE, a follow -up visit will be 
planned 4 weeks after the last dose of study  drug (Post Treatment
Week 4). Consequently , subjects are planned to be in the study  for 
approximately  32 weeks
During the screening period, information on demographics, medical 
history/concomitant diseases (including onset of RA, drug and alcohol 
use, and smoking habits), and prior RA medication will be collected. 
A physical examination ,vital signs, 12-lead electrocard iogram (ECG), 
and clinical laboratory  assessments will be conducted to determine the 
subject’s eligibility  for study  participation. 
At Day 1, after the subject’s eligibility  for the study  has been 
confirmed, the subject will be randomized into the study  to receive 
treatment with filgotinib 200 mg q.d., filgotinib 100 mg q.d, or 
placebo control  in addition to background therapy  with 
csDMARD(s). 
On-treatment assessments include adverse events (AEs), concomitant 
medication, review of study  medication compliance through study  
drug accountability , SJC66/TJC68, Phy sician’s Global Assessment, 
Subject’s Global Assessment, Subject’s Pain Assessment, HAQ
-DI, 
Functional Assessment of Chronic Illness Therapy-
Fatigue 
(FACIT-Fatigue), Short -Form Health Survey  (SF-36), Work 
Productivity  and Activit y Impairment -Rheumatoid Arthritis
(WPAI-RA), EuroQol 5 Dimensions (EQ-5D), Treatment Satisfaction 
Questionnaire fo r Medication (TSQM),  
, Healthcare Resource Utilization, physical examination, 
weight, vital signs, blood sampling for safet y laboratory  tests, and 
urine pregnancy  tests (for females of child bearing potential onl y).
PPD
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page11 05July2016A resting 12 -lead ECG should be performed at Screening, Week 12 , 
Week 24, or ET, and at the post dosing Week 4follow-up visit, as 
applicable .ECGs should be interpreted b y the investigator or qualified 
designee for clinical significance.
For all subjec ts, blood samples for PK anal ysis should be collected at 
least 30 minutes post study  drug dose on Week 4, prior to study drug 
administration on Weeks 12 and 24, and an ytime on Week 16 or  ET. 
 
 
Blood samples for biomarker anal ysis should 
be collected at Day  1, 
Week 4, Week 8, Week 12, Week 24 or ETand urine samples should 
be collected at Day  1, Weeks 12, and Week 24 or ET.
Post treatment follow -up assessments include AEs, conco mitant 
medications, phy sical examinations, 12 -lead ECGs, weight, vital 
signs, blood and urine sampling for safet y laboratory tests, and 
pregnancy tests (females of child bearing potential only ).
Test Product, Dose, 
and Mode of 
Administration:200mg filgotinib orally  
q.d.
100mg filgotinib orally  q.d.
Reference Therapy, 
Dose, and Mode of 
Administration:PTMfilgotinib 200 mg orally  q.d. 
PTM filgotinib 100 mg orally  q.d.
Required Backgound 
therapyPermitted csDMARD (s)as described in protocol and administered 
according to the local productlabel/standard of care .
Criteria for 
Evaluation:
Safety: Safety will be assessed by the documentation of AEs, clinical 
laboratory  tests, phy sical examination, vital sign s, and 12-lead ECGs 
during the stud y. 
Efficacy: The primary  endpoint is the proportion of subjects who achieve an 
ACR20response at Week 12.
The key secondary  endpoints are:
PPD
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page12 05July2016The proportion of subjects who achieve DAS28 (CRP) ≤3.2 at 
Week12
Change from baseline in the HAQ- DI score at Week 12
Pharmacokinetics: Plasma concentrations of filgotinib and its active metabolite 
(GS-829845) will be analy zed. 
Statistical Methods: The primary  analysis set for efficacy  analyses will be the Full 
Analysis Set (FAS), which includes all randomized subjects who
received at least one dose of study  drug.
The primary  endpoint is the proportion of subjects who achieve an 
ACR20response at Week 12. The primary  analysis will consist of a 
superiority  test of filgotinib 200 mg compared to placebo based on the 
ACR20 response rate at Week 12. 
Cochran-Mantel-Haenszel approach 
adjusting for the randomization stratification factors will be used for 
the hypothesistesting at the 2- sided 0.05
-level. 
The following h ypothesis testing will commence after the primary
analysis reaches statistical significance ,and will be tested according to 
the hierarchical testing principle at the 2 -sided 0.05 level . If a null 
hypothesis is not rejected, formal sequential testing will be stopped 
and only nominal significance will be reported for the remaining 
hypotheses:
1)Superiority  of filgotinib 200 mg compared to placebo based on 
the response rate of DAS28 (CRP) ≤3.2 
at Week 12 
2)Superiority  of filgotinib 200 mg compared to placebo based on 
the change from Baseline in HAQ-DI at Week 12
3)Superiority  of filgotinib 100 mg compared to placebo based on 
the ACR20response rate at Week 12 
4)Superiority  of filgotinib 100 mg compared to placebo based on 
the response rate of DAS28 (CRP) ≤3.2 at Week 12 
5)Superiority  of filgotinib 100 mg compared to placebo based on 
the change from Baseline in HAQ-DI at Week 12
All continuous endpoints will be summarized using an 8 -number 
summary (n, mean, standard deviation [SD], median, 1stquartile [Q1], 
3rdquartile [Q3], minimum, maximum) by  treatment group. All
categorical endpoints will be summarized by  the number and 
percentage of subjects who meet the endpoint definition.
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page13 05July2016Safety endpoints will be anal yzed by the number and percent of 
subjects with events or abnormalities for categorical values or 
8-number summary  (n, mean, SD, median, Q1, Q3, minimum, 
maximum) for continuous data by  treatment group.
Sample size is determined based on the superiority test of filgotinib 
groupscompared to placebo on the change from Baselinein HAQ-DI 
at Week 12. When assuming a difference of 0.25 between the two 
groups and a common standard deviation of 0.645, 141 subjects in 
each of the filgotinib group sand placebo control group are requ ired to 
obtain 90% power at a 2 -sided 0.05
-level. 
A sample size of 141 subjects in each of the filgotinib group sand 
placebo control group will also provide over 90% power to detect an 
increase in ACR20response rate of 25% to 45% between the placebo 
control group and the filgotinib group srespectively , using a 2- sided 
0.05-level test.
In summary , the total sample size will be 423
(141 per group) .
This study  will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) 
including archiving of essential documents.
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page14 05July2016GLOSSARY OF ABBREVIATIONS AND DEFINI TION OF TERMS
Ab antibody
ACR X American College of Rheumatology X% improvement
AE adverse event
ALT alanine aminotransferase
ANA anti-nuclear antibody
aPTT activated partial thromboplastin time
ATP adenosine triphosphate
AST aspartate aminotransferase
AUC0-Ʈ area under the plasma drug concentration -time curve of a dosing interval
bDMARD (s) Biologic disease modifying antirheumatic drug (s)
b.i.d. bis in die; twice daily
CƮ trough plasma concentration (just before the next dosing ie predose sample)
CCP cyclic citrullinated peptide
CD Crohn’s disease
CDAI Clinical Diagnostic Activity Index
csDMARD(s) Conventional disease modifying antirheumatic drug (s)
CES carboxylesterases
CIA collagen-induced arthritis 
Cmax maximum observed plasma concentration
CMV cytomegalovirus
CNS central nervous system
CRO Contract Research Organization
CRP C-reactive protein
CV-SEAC Cardiovascular Safety Endpoint Adjudication Committee
CYP Cytochrome P450
DAS28 Disease Activity Score based on 28joints
DBP diastolic blood pressure
DMARD(s) disease-modifying antirheumatic drug (s)
DMC data monitoring committee
dsDNA double stranded deoxyribonucleic acid
DSS dextran sulphate sodium
ECG electrocardiogram
eCRF electronic case report form
ET early termination
EU European Union
EULAR European League Against Rheumatism
EQ-5D EuroQol 5 Dimensions
FACIT-Fatigue Functional Assessment of Chronic Illness Therapy -Fatique
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page15 05July2016FAS Full Analysis Set
FDA Food and Drug Administration
FSH follicle stimulating hormone
GCP Good Clinical Practice
GFR glomerular filtration rate
GGT gamma glutamyl transferase
GI gastrointestinal 
GLP Galapagos
HAQ-DI Health Assessment Questionnaire –Disability Index
HCV hepatitis C virus
HCG human chorionic gonadotropin
HCQ hydroxychloroquine
HDL high density lipoprotein
hERG human ether -a-gogorelated gene
HIV human immunodeficiency virus
HR heart rate
IC50 half maximal inhibitory concentration
ICF informed consent form
ICH International Council for Harmonization
IEC Independent Ethics Committee
Ig Immunoglobulin
IMP investigational medicinal product
INR international normalized ratio
IRB Independent Review Board
ITT intent-to-treat
IWRS Interactive web response system
JAK janus kinase inhibitor
LCMS/MS liquid chromatography mass spectrometry
LDL low density lipoprotein
LH luteinizing hormone
LTE Long Term E xtension
MACE major adverse cardiovascular event
MCV mean corpuscular volume
MTX methotrexate
MTX-IR inadequate response to Methotrexate
NSAIDs nonsteroidal anti -inflammatory drugs
NOEL no-observed-effect-level
NYHA New York Heart Association
OATs organic anion transporters
PK pharmacokinetics
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page16 05July2016PP per-protocol
PT prothrombin time
PTM Placebo to match
q.d. quaque die; once daily
RA rheumatoid arthritis
RF rheumatoid factor
SAE serious adverse event
SAP Statistical Analysis Plan 
SBP systolic blood pressure
s.c. subcutaneous
SD standard deviation
SDAI Simplified Diagnostic Activity Index
SF-36 short-form health survey
SI international system of units
SJC66 swollen joint count based on 66 joints
SOC Symptom Organ Class
TB Tuberculosis
TEAEs Treatment emergent adverse events
TJC68 tender joint count based on 68 joints
tmax the time of occurrence of maximum observed plasma concentration
TNFα tumor necrosis factor alpha
TSQM Treatment Satisfaction Questionnaire for Medication
UGTs uridine disphosphate glucuronosyltransferase s
ULN upper limit of normal
US United States
vs. versus
WBC white blood cell
WPAI-RA Work Productivity and Activity Impairment -Rheumatoid Arthritis
Definition of Terms
QTcF QT interval corrected for HR according to Fridericia’s formula:
QTcF = QT/(RR)^(1/3), where RR = 60/HR
RR = R-R interval in seconds
HR = heart rate in beats per minute
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page17 05July20161. INTRODUCTION
1.1. Background
Rheumatoid arthritis (RA) is a chronic, s ystemic inflammatory  disease that affects approximately  
1.3 million adults in the United States (US) {Helmick et al 2008 }. Rheumatoid arthritis 
manifests principally as an attack on peripheral joints and may lead to marked destruction and 
deformity  of joints, with considerable disabilit y and impact on quality of life. I t is characterized 
by the production of autoantib odies,synovial inflammation with formation of pannus tissue, and 
erosion of underl ying cartilage and bone. Although people of any  age can be affected, the onset 
of RA is most frequent between the ages of 40 and 50 y ears, and women are affected 3 times 
more often than men. While the cause of RA is still not completely  understood, aberrant B -cell 
activation, T -cell co-stimulation, osteoclast differentiation, and cytokine release all have been 
implicated in its pathogenesis.
Treatment of RA is dependent on se verity, the patient’s co –morbidities and initial response to 
therapy. Methotrexate (MTX) is a conventional disease modify ing anti-rheumatic drug 
(DMARD) and continues to be the cornerstone of RA therap y {Singh et al 2012 }. Patients with 
an inadequate response to conventional DMARD(s) are often treated with biologic therapies such 
as tumor necrosis factor inhibitors (TNFi) as an initial second line therap y. However, 
approximately  28% to 58% of R A patients with inadequate response to MTX fail TNFi as 
reviewed in {Redlich et al 2003 }
. In this setting, treatment guidelines recommend either
switching to another TNFi, alternate biologic, or to a small molecule drug {Singh et al 2012 }. 
Despite signi ficant advances in disease management in recent years, there remains a need for 
new treatments, since not all patients respond adequately to current therapies, ha ve 
co-morbidities and some patients experience toxicities and/or intolerance that limit the us e of 
approved therapies.
In November 2012, tofacitinib (Xeljanz®) became the first Janus kinase (JAK)inhibitor to 
receive Food and Drug Administration (FDA) approval for the treatment of adult patients with 
RA. Tofacitinib is a small molecule, has strong binding affinity  for JAK1 and JAK3, and weaker 
affinity for JAK2. The extensive pre -clinical and clinical development programs demonstrated its 
mechanisms of action via anti -inflammatory  and immunosuppressive effects. The drug proved to 
be efficacious in t reating the signs and s ymptoms of RA. However, the observed side
-effects and 
risk profile of tofacitinib are similar to those of several existing anti -rheumatic agents with 
cytopenias, elevated levels of liver function enzymes, increased  total cholesterol levels, with
increases in LDL typically exceeding those for HDL, and increased risk for infections including 
serious and opportunistic infections. At higher doses, tofacitinib treatment was associated with 
anemia, which is thought to be linked to inhibiti on of JAK2. 
While the pan JAK inhibitor tofacitinib has shown an earl y onset of action and long -term 
efficacy in RA as monotherapy and in combination with background conventional disease 
modifying anti-rheumatic drug s (csDMARD s) therapy, dose levels were limited by  side effects 
potentially  mediated b y its effect on JAK 2 and JAK 3. This highlights the need for more 
selective and targeted therapies with improved immunomodulatory  and hematologic effects. 
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page18 05July2016JAK1 is thought to be an integral part of RA pathogene sis due its role in transmitting 
inflammatory  cytokine signaling. Hence, targeted inhibition of JAK1 has great potential for the 
treatment of RA with an improved safet y and side effect profile. 
1.2. Filgotinib
1.2.1. General Information
Janus kinases are intracellular cy toplasmic ty rosine kinases (TYKs) that transduce cy tokine 
signaling from membrane receptors through signal transducer and activator of transcription 
(STAT) to the nucleus of cells. JAK inhibitors block the signaling of various cy tokines, gr owth 
factors, and hormones, including the pro -inflammatory  cytokine interleukin (IL) -6. Four 
different t ypes of JAKs are known, JAK1, JAK2, JAK3, and TYK2 which co -interact with 
different sets of membrane receptors. Inhibition of JAKs is a promising therap eutic option for a 
range of inflammatory  conditions including RA and Crohn’s Disease (CD).
Filgotinib (GS-6034, formerly  GLPG0634) is a potent and selective inhibitor of JA K1. The 
compound has shown good preliminary  efficacy in RA and CD patients in Phase 2. No ty pical 
JAK2 side effects such as anemia were observed in clinical studies of up to 24 weeks duration. 
In humans, filgotinib is metabolized to form one major active metabolite, GS-829845
(formerlyG254445). Though the potency  of this metabolite is l ower than the parent molecule, 
the overall exposure and peak plasma concentration in humans is higher than seen in all tested 
animal species. As a consequence, dedicated pharmacology and toxicology studies have been 
performed with GS-829845.  Results from pharmacodynamics (PD) testing in healthy  volunteers 
suggest that the clinical activity  of filgotinib could result from the combination of the parent 
molecule and the metabolite.
For further information on filgotinib, refer to the current investigator’s bro chure.
1.2.2. Nonclinical Pharmacology,
Absorption, Distribution, Metabolism, and 
Excretion (ADME) and Toxicology
Filgotinib and its metabolite, GS -829845havebeen extensively  characterized in nonclinical 
studies. This program includes cellular assay s demonstrat ing potency  and selectivity  of the 
compound against JAK1; efficacy  studies in rats and mice; repeat dose toxicity  studies 
(upto26weeks in the rat and 39 weeks in the dog), in vitroand in vivosafety pharmacology  and 
genetic toxicology  studies, and repr oductive toxicology  studies in rats and rabbits. Additional 
toxicology  studies conducted include phototoxicity  studies and dose -range finding studies in 
support of a definitive rat juvenile toxicity  study and a 6 month carcinogenicity  study in 
transgenic ( TgrasH2) mice. A 2 y ear rat oral carcinogenicity  study is ongoing.
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page19 05July20161.2.2.1. Primary and Secondary  Pharmacology
Filgotinib is an adenosine triphosphate (ATP) -competitive inhibitor of JAK1. I t is highly 
selective for inhibition of JAK1 over451 other kinasesevaluated in vitro.In cellular assay s, it 
inhibits JAK/STAT- driven processes with half maximal inhibitory  concentration (I C50) values 
from 179 nM onwards. In human whole blood, JAK1 is inhibited by  
filgotinib with an IC50of 
629 nM and exhibits approxima tely 30-fold selectivity  over JAK2. Filgotinib demonstrated 
significant efficacy  in the rat collagen -induced arthritis (CI A) model as well as in the mouse 
dextran sulphate sodium (DSS) -
induced colitis model.
Metabolite GS-829845exhibits a similar JAK1 sel ectivity profile but is approximately  10to 
20-fold less potent than the parent filgotinib in in vitroassays. GS-829845was as effective as 
filgotinib in the rat CIA model, but at doses that required a 10 -fold higher exposure.
1.2.2.2. Safety Pharmacology
Filgotin
iband GS-829845had no effects on the respiratory  system and central nervous s ystem 
(CNS) up to respectivel y 40-and 5-fold the exposure in RA subjects givenfilgotinib 200 mg q .d.
Filgotinib and GS-829845had no relevant effects on cardiovas cular paramet ers (human 
ether-a-gogorelated gene [hERG] and dog telemetry  studies), apart from a slight non- adverse 
increase in heart rate and arterial pressure with GS-829845 at exposures 7- fold that of the C maxin 
subjects with RA treated with 200 mg q .d.filgotinib. There were no relevant effects on 
electrocardiogram (ECG) and QT.
1.2.2.3. Nonclinical ADME
Filgotinib demonstrates good oral bioavailability in mice, rats, dogs, and minipigs but less in 
monkeys. Plasma protein binding is low (< 70%) in all species, including humans.
The pharmacokinetics (PK) of filgotonib is generally dose proportional without gender 
differences. No accumulation occurs with repeated dosing. The mean terminal half -life after oral 
administration is 4 and 5 hours (h) in rats and dogs, respective ly.
In the rat, filgotinib showed a rapid and even distribution throughout the body . 
High 
concentrations were observed only in the gastrointestinal (GI) tract and urinary  bladder. 
Filgotinib does not penetrate into central nervous sy stem (CNS)tissues. Thedistribution of 
filgotinib indicates some affinity  for melanin- containing tissues.
Excretion is nearly  complete within 24 h (rat) and 48 h (dog) post -dosing. In the 
rat, fecal and 
urinary excretion accounted for 40% and 53% of the administered dose, re spectively, with a bile 
secretion of about 15%. Inthedog, fecal excretion was the primary  route of excretion, 
accounting for 59% of the administered dose, with urinary  excretion accounting for 25% .
In vitrometabolism studies in all species revealed one major metabolite ( GS-829845). The 
formation of GS-829845is mediated by  carboxylesterases (CES) and is not dependent on 
cytochrome P450 (CYP).
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page20 05July2016In vitroexperiments have shown that drug- drug interactions with filgotinib and GS -829845 are 
unlikely.  There is no inhibition or induction of CYPs or uridine disphosphate 
glucuronosy ltransferase s (UGTs), and no relevant inhibition ofkey drug transporters, including 
the organic anion transporters (OATs) involved in the renal elimination of MTX , by filgotinib or 
GS-829845 .
1.2.2.4. Nonclinical Toxicology
In repeat oral dose toxicity  studies in both rats and dogs, the primary  target tissues identified for 
filgotinib were the l ymphoid tissues which is expected based on the pharmacology of JAK 
inhibition. Additional filgotinib-related findings were observed in the male reproductive organs 
of both species, and in the incisor teeth of rats only. Effects on the l ymphoid system were full y 
reversible. Testicular toxicity  demonstrated partial reversibility  however sperm counts remain ed 
low. A dose of 200 mg/day of filgotinib result edin an estimated mean clinical AUC of 
2.80μg∙h/mL, which represents an exposure margin of 2.3, 1.8, and 3.4 -fold when considering 
the mean AUC in male dogs at the no -observed- effect-levels (NOELs) 
inthe 26weekand 
39week chronic toxicology  studies,and the 
39 week targetedexposure toxicity  study, 
respectivel y. 
GS-829845-related findings in general repeat dose toxicity  studies were similar to those of the 
parent filgotinib, however no testicular toxici ty was noted following administration of 
GS-
829845.
Filgotinib and GS-829845were non-genotoxic when evaluated in the bacterial mutagenicit y 
assay, the in vitro mouse lymphoma mutagenicit y assay, and the rat bone marrow micronucleus 
assay.
In embryofetal development studies, filgotinib and GS-
829845caused embry olethality and 
teratogenicit y in rats and rabbits at exposures similar to the human exposure at 200 mg q .d.of 
filgotinib in subjects with RA. Administration of filgotinib did not af fect female fertility  but 
impaired fertility  was observed in male rats at exposures approximately  15-fold the human 
exposure at 200 mg of filgotinib in subjects with RA. GS-
829845did not have an y effects on 
fertility parameters in either male or female ra ts.
In an in vitrophototoxicity  study in 3T3 cells, the metabolite GS-829845was positive for 
phototoxic potential and results with filgotinib were equivocal. A follow
-up in vivorat 
phototoxicity  assay revealed a lack of phototoxic potential for both com pounds.
1.2.3. Clinical Trials of Filgotinib
Comprehensive data from the Phase 1 and 2 programs are available to support development into 
Phase 3. As of January  2016, filgotinib has been administered to more than 150 healthy subjects,
more than 1000 RA subjects, andmore than 150 subjects with CD. A detailed description of all 
clinical studies can be found in the Investigator’s Brochure ( IB). 
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page21 05July2016Phase 2b G LPG0634-CL-203, filgotinib with MTX in RA
In GLPG0634-CL-203, subjects with acti ve RA on stable dose of MTX were randomized to
receiveeitherplacebo or one of three total daily dosesof filgotinib (50 mg, 100 mg,or
200 mg)on a once ortwice dailyschedule for 24 weeks. The primaryobjective ofthestudywas
toevaluatethe efficacyofdifferent dosesand dose regimens off ilgotinib compa red to placebo at 
Week12.
Thepercentage ofAmerican College of Rheumatology (ACR) 20 responderswasstatistically
significantlyhigherin the 100mgand 200mgoncedaily, and 100 mgtwicedailydosegroups
atWeek12 andinthe 100mgand 200 mg once daily, and 50 mgand100mgtwicedaily 
dosegroupsatWeek24.ThepercentageofACR50responderswasstatisticallysignificantly
higher compared withplacebo acrossallfilgotinibdosegroups andregimensatbothWeeks 12
and 24 (Table1-1).The percentage ofACR70 responderswas statistic allysig nifican tlyhigher in
the filgotini
b200 mg o nce daily and 100mgtwicedailydosegroupscompared withplaceboat
Week12 a
ndacrossallfilgotinib dose groups andregimensatWeek24. Adose-responsewas
observedforallthreeparameters. Inaddition, theACR20responseappearedtoplateau at
Week8 in themajority of filgotinibtreatm entgroups and w asmaintaineduptoWeek 24. A t
Week 24, t he ACR50responsewasmaintaineda nd theACR70 response continued to i ncreases
compared w ithWeek12.
Starting at week 2 response wasobserved forACR20andACR50.Nostatistically significant 
diffe
rencewasfoundbetween the onceandtwicedailyregimens.
Table1-1. Summary and 
analysis of ACR20/50/70 response at Weeks 12 and 
24 (NRI [ITT Population]), GLPG0634- CL-
203
Parame
terTime
PointPlacebo
N=86FilgotiniboncedailyDoseGroups FilgotinibtwicedailyDoseGroups
50 mg
N=82100mg
N=85200mg
N=8625 mg
N=8650 mg
N=85100mg
N=84
n(%)
ACR20 W1238 (44.2) 46 (56.1) 54 (63.5)* 59 (68.6)** 49 (57.0) 51 (60.0) 66 (78.6)***
W2436 (41.9) 45 (54.9) 52 (61.2)* 63 (73.3)*** 48 (55.8) 51 (60.0)* 67 (79.8) ***
ACR50 W1213 (15.1) 27 (32.9)* 32 (37.6)** 37 (43.0)*** 24 (27.9)* 29 (34.1)* 46 (54.8)***
W2414 (16.3) 29 (35.4)** 40 (47.1)*** 43 (50.0)*** 30 (34.9)** 30 (35.3)** 46 (54.8)***
ACR70 W12 7 (8.1) 13 (15.9) 18 (21.2) 21 (24.4)* 12 (14.0) 16 (18.8) 26 (31.0)**
W24 8 (9.3) 18 (22.0)* 28 (32.9)** 25 (29.1)** 18(20.9)* 20 (23.5)* 33 (39.3)***
Note1:p-valueswerebasedona pairwisecom parisonsofeach groupvs. theplace bogroupusinga lo gisticregressionmodel
with factorstreatmentgroup,geographicalregion,andpriorus e ofbiologi cs;Hommel-correctedp-val ue. Note2:The
denom
inatorfor the percentagecalculations=thetotal numberofsu bjectsper gro upwitha response(yesor no)atthattimepoint
Note3:Subjectswhoswitc hedtreatmentat Week12werehandled asiftheydiscontinuedat Week12.
*p<0.05;**p<0.01;***p <0.001
ACR=AmericanCollegeof Rheumatology;ITT =Intent-to-treat;NRI=non-responderimpu tation;W=week
Source:GLPG0634-CL-203
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page22 05July2016At both W eeks 12 and 24 the me andecreasein DAS28(CRP)(Appendix 10) was
stati
stically significantly greater acrossallfilgotini b dose groups compared w ith plac ebo. A
dose-response was observed. Nos tatis ti cally significant diff erencewas apparentbetweenthe 
once and twicedailyregimens. At both W eeks 12 and 24, the me andecreaseinSimplified 
Diagnostic Activity Index(S
DAI)and Clinical Diagnostic Activity  Index(CDAI)scorewas
statistically significantly greater acrossall filgotinib dosegroups and r egimens compared with
place
bo(with the exception of filgotinib 50 mg once dailydosegr oupatWeek12). In addit ion,
the m
eanSDAI and C DAI scores weremaintained after Week 12 in the 50 mgdailydose
groups and continued to improve up to Week 24 inthe 100 mg and 200 mg dailydose groups.
No unexpected safety  findings were noted. Overall, no differences were observed in the 
incidence of treatment emergent adverse events ( TEAEs)reported for subjects in an y of the 
dosinggroups, including placebo, for the duration of the study . TEAEs were reported for 
51.2%
of “All Placebo Exposed” subjects (ie, all subjects combined who received placebo during 
either the entire 24 weeks or only  during the first 12weeks) and 51.5% of “All filgotinib
Exposed” subjects (ie, all subjects combined who received filgotinib during either the entire 
24weeks or only during the last 12 weeks, irrespective of dose).
A total of 15 subjects had ≥1 serious TEAE; 4 subjects in the placebo group (4.7%) and 
11subjects (2.0%) in one of the filgotinib groups. One subject of these subjects with ≥1 serious 
TEAE, who re ceived filgotinib 100 mg bid twice daily  with concurrent MTX , died during the 
second 12 weeks of the treatment period due to pneumonia and septic shock. Out of the 
15 subjects with a serious TEAE, 11 subjects had a serious TEAE due to which the study  
medication was stopped and the subject discontinued the study . A total of 23 subjects had ≥1 AE 
leading to permanent discontinuation of the study medication and the study; 2 subjects (2.3%) in 
the placebo group and 21 subjects (3.9%) in one of the filgotinib groups (including a subject in 
the filgotinib 100 mg q .d.group who had a pre -doisngAE which was ongoing throughout the 
study, for which the study  medication was permanently  discontinued). Most of the serious 
TEAEs and the AEs leading to discontinuation (by preferred term) were experienced by  a 
singlesubject.
For the duration of the study , the most common ( ≥10%) TEAEs reported by  SOC in subjects 
from both the placebo and filgotinib dosinggroups, were Infections and Infestations and 
Gastrointestinal disorde rs. There were no differences between subjects who received placebo or 
filgotinib in the severit y of TEAEs (most TEAEs were mild or moderate; severe TEAEs were 
observed in 1.2% of “All Placebo Exposed” subjects and in 2.2% of “All filgotinib Exposed” 
subjects). Treatment- related TEAEs were generally  reported more often for subjects in the 
filgotinib treatment groups than in the placebo group (9.3% with placebo and 20.3% with 
filgotinib
); however, within the different filgotinib dosinggroups, no clear dose relationships 
were observed.
Sixserious infections were reported (1 inplaceboarm, 5 infilgotinib). All 6 serious and 
oneadditional non- serious infection in the 
filgotinib group led to dosingdiscontinuation. Up to 
Week24, herpes zoster i nfections were observed in 5 subjects (1 placebotreated patient and 
4filigotnib ). No cases of tuberculosis, opportunistic infections, ly mphoma, or cancer were 
reported throughout the 24
-week dosingperiod.
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page23 05July2016Laboratory  data were consistent with prior Phas e 2 studies and no new safety  findings were 
observed from laboratory data. A summary  of laboratory  findings of interest, including 
hemoglobin, neutrophil, ly mphocyte, creatinine, lipid, and hormone data are summarized below. 
Up to Week 12, small increases were observed in mean hemoglobin concentrations in the 
filgotinib 200 mg dail y dose groups (increase of 4.4 g/L from Baselinein the filgotinib 100 mg 
bid group). Thereafter, hemoglobin mean concentrations appeared to plateau and remained stable 
until Week 24 (increase of 4.9 g/L from Baseline in the filgotinib 100 mg bid group) . Up to 
Week 4, dose
-dependent decreases were observed in mean absolute neutrophil counts in the 
filgotinib treatment groups. Mean absolute neutrophil counts appeared to plateau and remained 
stable until Week 24. No decreases in mean absolute ly mphocyte counts were observed, 
including l ymphocyte subsets. Up to Week 4, dose -dependent decreases were observed in mean 
absolute platelet counts in the filgotinib treatment groups. Meanabsolute platelet counts 
appeared to plateau and remained stable. Dose- dependent increases in the filgotinib groups were 
observed in mean creatinine concentrations during the first 4 weeks of the study  for most 
filgotinib treatment groups (up to Week 8 fo r the filgotinib 100 mg bid group) that subsequently  
plateaued and remained stable up to Week 24. Up to Week 4, dose -dependent increases were 
observed in mean concentrations of total cho lesterol, L DL cholesterol, high -density lipoprotein 
(HDL) cholesterol, and triglycerides in all 
filgotinib treatment groups. All these lipid parameters 
further increased up to Week 8 in the filgotinib 200 mg dail y dose groups. Thereafter, these 
increases appeared to plateau and maintained at stable mean concentrations up to Week 24. At 
Week 24, mean increases were observed of 0.7 mmol/L  in total cholesterol, 0.3 mmol/L  in LDL 
cholesterol, 0.3 mmol/L in HDL cholesterol, and 0.1 mmol/L in triglycerides in the filgotinib
100mg bid group.
In male subjects, small non dose -dependent increases were observed in total and free testosterone 
during the stud y (at Week 24, mean increases were 3.4 nmol/L  for testosterone and 51.7 pmol/L  
for free testosterone in the filgotinib 100mg bid group). For FS H, inhibin B, LH, and prolactin, 
small changes (both increases and decreases) were observed during the study , without any  trends 
of larger changes in male subjects of one or more of the different treatment groups.
GLPG0634-CL-204, F ilgotinib administere d as monotherapyinRASubjects
Thepr
imaryobjectiveof studyGLPG0634-CL-204wasto evaluate theefficacyofthree 
doses of filgotinib q.d. comparedtoplacebo atWeek12.
AsshowninTable1-2,thepercentage ofACR20andACR50responders at week 12was
statistically significantly higheracrossallfilgotinib dosegroupscompared withplacebo.The
percentage ofACR70responders inthefilgotinib 100 mgand 200 mg oncedaily dosegroups 
wasstatistically significantly highercompared withplacebo. AtWeek24,theACR50response
wasmaintained andtheACR70 response 
showed continued improveme
nt.An early onset of 
responsewasobserved forACR20(fromWeek1inthefilgotinib 200 mg oncedaily dose
groupandWeek4 acrossallotherdosegroups), ACR50(fromWeek 2 
inthe filgotinib 20 0 mg 
oncedaily dosegroupandWeek4acrossallotherfilgotinib dosegroups),andACR70 
(Week 4inthefilgotinib 200mgoncedailydosegroup). ThetimetoACR20/50/70 response 
wasshorterin allfilgotinib dosegroupscompared with placebo
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page24 05July2016Table1-2. Summary and analysis of ACR20/50/70 response at Weeks 12 and 24 
(NRI [ITT Population]); GLPG0634-0204
ParameterTime
PointPlacebo Filgotinib once daily Dose Groups
N=7250 mg
N=72100 mg
N=70200 mg
N=69
n (%)
ACR20 W12 21 (29.2) 48 (66.7)*** 46 (65.7)*** 50 (72.5)***
W24 Not applicable 41 (56.9) 55 (78.6) 46 (66.7)
ACR50 W12 8 (11.1) 25 (34.7)*** 26 (37.1)*** 30 (43.5)***
W24 Not applicable 24 (33.3) 27 (38.6) 31 (44.9)
ACR70 W12 2 (2.8) 6 (8.3) 13 (18.6)** 9 (13.0)*
W24 Not applicable 14 (19.4) 18 (25.7) 17 (24.6)
Note 1: p-values were based on a pairwise comparisons of each group vs. the placebo group using a logistic regression model 
with factors treatment group, geographical region, and prior use of biologics; Hommel -corrected p -value.
Note 2: The denominator for the percentage calculations = the total number of subjects per group with a response (yes or no) at 
that time point
Note 3: Subjects who switched treatme nt at Week 12 were handled as if they discontinued at Week 12.
* p< 0.05; **  p< 0.01; *** p < 0.001
ITT=Intent-to -treat; NRI=non -responder imputation; W=week
Source: GLPG0634 -CL-204
At Week 12, the m ean decreasein DAS28(CRP) was statis tically significantly greater across all 
filgotinib dose groups compared with placebo . Week 24, the mean decreasein DAS28(CRP)
wasmaintained in the 50 mgoncedaily dos e group and sh owed asmall improvement in the
highestdose groups.In addition,atWeek 12, the pe rce ntage of su bjects with DAS28(CRP)
rem
ission washigheracrossa ll filgotini b dosegroups co mpared with pl aceboatWeek 12.
Differenc
es vs.placebo were not sta tistical lysig nificant for anyof the f ilgotinib dose groups.
The numbe
r of subjects with DAS28(CRP)<2.6 and <3.2 werehigheracrossall filgotinib
dosegroups comparedwith placeboatWeek12; differences vs. placebo werest atistically
significant for the f ilgo tinib 200 mgoncedaily dosegroup.
Safety data revealed no differences in the incidence of TEAEs reported for subjects in any  of the 
treatment groups, including placebo, during both the first 12 wee ks of treatment and the full 
24weeks of treatment. TEAEs were reported for 38.9% of “All Placebo Exposed” subjects 
(ie,all subjects combined who received placebo during the first 12 weeks) and 41.3% of “All 
filgotinib Exposed” subjects (ie, all subjects combined who received filgotinib during either the 
entire 24 weeks or onl y during the las t 12 weeks, irrespective of dose).
Nodeathswerereportedandatotalof9subjectshadaseriousTEAE;1subject(1.4%)during
placebodosingand8subjects(2.9%)duringfilgotinib dosing.NoseriousTEAE(bypreferred
term)wasexperienced bymorethan1subject,andallsubjectsrecovered fromtheirserious
TEAEs.Outofthe9subjectswithaseriousTEAE,3hadaseriousTEAEforwhichthestudy
medication wasstoppedandthesubjectdiscontinued thestudy.Therewerenodifferences in
incidences of AEsleadingtodiscontinuation amongallthedifferentdosinggroups,including
placebo.Atotalof11subjectshad≥1TEAEleadingtodiscontinuation ofthestudymedication;
4subjects(5.6%)duringplacebodosingand7subjects(2.5%)duringfilgotinib dosing.
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page25 05July2016Throughout the study, the most common TEAEs reported by  System Organ Class in subjects 
from both the placebo and filgotinib treatment groups, were ‘Infections and I nfestations’ and 
‘Gastrointestinal disorders’. There were no differences between subjects who received placebo or 
filgotinib in the severit y of TEAEs (most TEAEs were mild or moderate; severe TEAEs were 
observed in 1.4% of “All Placebo Exposed” subjects and in 1.1% of “All filgotinib Exposed” 
subjects). Treatment-related TEAEs were general ly reported more often for subjects in the 
filgotinib treatment groups than in the placebo group (9.7% with placebo and 16.7% with 
filgotinib); however, within the different filgotinib treatment group, no clear dose relationships 
were observed.
Low numbers of infections were reported as serious (4 subjects with filgotinib) or led to 
discontinuation of the study  medication (2 serious infections; ie, cellulitis and pneumonia) were 
observed during the study. Up to Week 24, 1 subject (filgotinib 50 mg q.d. group) had a herpes 
zoster infection. No cases of tuberculosis, opportunistic infections, l ymphoma, or cancer were 
reported throughout the 24-week treatment period.
Laboratory  data were consistent with prior studies and no new safet y findings were observed .
Please refer to the IB for additional data for efficacy  endpoints and safety .
1.3. Rationale for This Study
Over the last decade, changes in RA treatment strategies, accompanied b y advances in drug 
development and the addition of targeted biological t herapies, have greatl y improved the 
outcomes for subjects with RA. Despite these developments, therapeutic challenges remain. The 
current conventional and biologic DMARDs may be ineffective or produce only  partial 
responses in some subjects and may  beassociated wit h significant safet y and tolerability 
concerns. There is a medical need for simple, orally  administered therapies with novel and 
targeted mechanisms of action that can effectivel y improve the disease course while being safe 
and well-tolerated.This need is especially  pronounced for subjects that have had an inadequate 
response or are intolerant to bDMARDs, as they  may have limited options remaining for further 
treatment. 
Filgotinib is an orall y administered, small molecule inhibitor of JAK1 an intracellula r tyrosine 
kinase that is dy sregulated in subjects with inflammatory  disorders including RA. Filgotinib has 
demonstrated clinical activity  and a favorable safety  and tolerability profile in Phase 2 studies in 
subjects with moderatel y to severel y active RA.
1.3.1. Rationale for Study Design
GS-US-417-0302 is a P hase3 randomized, double -blind, placebo -controlled study  designed to 
evaluate the efficacy  and safet y of filgotinib in subjects with active RA despite csDMARD (s)
therapy who have failed treatment with or had intolerance to at least one bDMARD . The 
objectives of the stud y are to evaluate the efficacy of filgotinib on the signs and symptoms of 
RA, to evaluate its effect on phy sical function, work productivity , fatigue, and quality  of life. In 
addition, th e safety, tolerability ,and pharmacokinetics (PK), will be assessed.
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page26 05July2016All subjects in this study  are required to maintain therapy with background cs DMARD(s). 
Methotrexate is the most commonly  prescribed first line c sDMARD in the treatment of 
moderatel y to severely active RA and has been shown to reduce the signs and symptoms of 
diseaseas well as to inhibit radiographic progression
{Lopez-Olivoet al 2014 }. Theplacebo 
control used in this study will allow assessment of thefilgotinib safety and tolerability  profile 
andestablish the efficacy contribution that filgotinib may  provide 
in combination with
csDMARD (s). Duration of placebo will be limitedin inadequate responders whowill 
discontinue investigational therap yat Week 14 but will continue with study  visits and 
assessments per protocol. A ll subjects who discontinue from investigational therap y, are to 
receive standart of care treatment for their RA as determin ed by the investigator. Inclusion of a
placeboarmin addition to background therapywill enable discernment of the true added effect 
of filgotinib. Given the slow ly progressive nature of RA, 14 weeks of placebo in Non-responders 
on accepted background therap y is considered both clinically  and ethicall y appropriate and 
allows an acceptable time to assess initial response to therap y. The use of placebo is additionally 
critical when evaluating patient reported and subjective outcomes , which can be highly  variable 
and influenced b y placebo therap y. The placebo effect is well established in RA therap y and 
inclusion of the placebo arm is critical in evaluating the overall risk:benefit balance of added 
filgotinib therap y. Finally, the pro vision of best supportive care in the context of the trial, as well 
as the limited duration and eventual opportunity for subjects to enterthe LT Efilgotinib, make the 
use of placebo ethically acceptable for the duration noted, especiall y in patients who ha ve 
already failed multiple lines of therap yand for whom no single standard of care is accepted.
The studyeligibility  criteria are consistent with those of recent clinical trials evaluating novel 
investigational treatments for RA. Subjects will meet the 2 010 ACR/ European League Against 
Rheumatism (EULAR) diagnostic criteria for RA. I n addition, subjects are required to have 
active disease defined as ≥6swollen and 
≥6tender joints at both Screening and Day  1.
1.3.2. Rationale for the Outcome Measures
Safety and tolerability  will be assessed by  the evaluation of adverse events (AEs), selected 
clinical laboratory  parameters, vital signs, phy sical examinations ,and ECGs, all of which are 
standard safety evaluations in clinical research studies.
The ACR20, ACR50, and
ACR70 responses and the DAS28 (CRP) are considered reliable 
measures of response to treatment and disease activity , respectivel y in subjects with RA. 
Comparison between the treatment groupsof the proportions of subjects achieving an ACR20 
response at Wee k 12 and the proportions of subjects achieving DAS28 (CRP) ≤3.2allows for 
straightforward interpretation of a clinicall y meaningful response and these measures have been 
shown to achieve high discriminatory  capacity.
Evaluation of continuous outcome measu res of DAS28 and ACR -N as secondary  endpoints 
enables the demonstration of improvement and magnitude of benefit. The EULAR response 
criteria classify  subjects as non- , moderate -, or good responders depending on the extent of 
change and the level of disease activity reached. These response criteria are useful when 
describing clinicall y meaningful therapeutic results. The Clinical Diagnostic Activity Index 
(CDAI) and the Simplified Diagnostic Activity  Indes(SDAI)have been widely  used in clinical 
studies to demonstrate the impact of a stud y drug on controlling disease activity.
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page27 05July2016Assessing qualit y of life (measured b y the Functional Assessment of Chronic I llness Therapy  
[FACIT-Fatigue], 36-item short form health sur vey [SF-36], and EuroQol 5 -Dimension 
[EQ-5D]) at Day1 and during the course of study  treatment provides insight into the effects on 
modifying disease course and impact on dail y life. Treatment satisfaction will be assessed by  
using the Treatment Satisfact ion Questionnaire for Medication (TS QM) at Day 1 and during the 
course of the stud y. Assessing the change in economic impact (Work Productivity  and Activity  
Impairment [WPAI ] and Healthcare Resource Utilization) of RA over the course of the stud y 
provides insight into the subject’s ability  to work and other dail y activities as well as the impact 
on the burden of healthcare resources.
1.3.3. Rationale for the Choice of Dose and Dosing Interval
Enrolled subjects will be randomized to receive filgotinib or placebo. T he 100 mg q.d. 
and 
200mg q.d. dose of filgotinib are based on efficacy , tolerability , and safet y data derive d from 
thePhase1 and Phase 2 studies.
In sevenPhase1 studies conducted in healthy  subjects ( GLPG0634-CL- 101,-102, -103,-104, 
-105, -107, and-110), filgotinib administered at doses up to 450 mgq.d.for up to 10 days was 
safe and well -tolerated.
In the two Phase 2a studies in subjects with RA (Study GLPG0634- CL-201 and -202), 
dosing 
with filgotinib was well tolerated and achieved a high level of efficacy at a 200 mg daily dose
(ACR20 response of 75 -92% at Week 4) . Administration of a higher filgotinib dose (300 mg) did 
not demonstrate greater efficacy , therefore, the highest dose to be tested in this study  will be 
200mg q.d.
In two Phase 2b studies, filgotinib at total daily  doses of 50 mg, 100mg, or 200mg, 
administered in addition to a background therap y with MTX (GL PG0634-CL-203) or as 
monotherap y (GLPG0634 -CL-204) was shown to be safe and efficacious in subjects with 
moderately to severel y active RA who had an inadequate response to MTX alone(Section 1.2.3).
Exposure-response anal ysis based on d ata from all Phase 2 studies indicated a dose -dependent 
increase in efficacy  (ACR20/50/70, DAS28[ CRP]), with a plateau at the 200 mg total dail y dose 
on the dose -response curve. Additionally , in Study GLPG0634‑
CL‑203, no statistically  
significant difference in efficacy  was observed at 200 mg q.d.daily dose, administered as 
200mg q.d.or 100 mg bid . These results are consistent with the relationship observed between 
filgotinib exposures and pSTAT1 activation (ex -
vivo) following single and multiple filgotinib 
doses where maximal inhibition of pSTAT1 (~78%) was achieved at or above 200 mg total dail y 
dose and intermediate inhibitio n (~47
%) at 100 mg {Namour et al 2015 }. 
Safety data collected across Phase 2 clinical studies showed no dose -dependent trends in the 
incidence of AEs or SAEs, including infections, or laboratory  abnormalities with the exception 
of numerical increase in select gastrointestinal AEs (eg, nausea, vomiting, abdominal pain, and 
upper abdominal pain .This numerical increase was observed in the 200 mg compared to the 
100mg dose. However, the overall freq uency was low and clinical relevance is unknown. 
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page28 05July2016Filgotinib, administered at a dose of 100 mg or 200 mgdaily was found to be safe and well 
tolerated. The safet y profile was consistent with that observed for an immunomodulatory  
compound administered to subjects with RA.
Overall, the 100 mg and 200 mg once -daily dose regimens have been proposed based on the 
safety and efficacy data from the Phase 2 studies in RA and the observed plateau in the pSTAT1 
response which indicates doses above 200 mg are unlik ely to add additional benefit. Inclusion of 
multiple doses in the proposed Phase 3 trials will enable establishment of an appropriate nominal 
dose for the treatment of RA and determine the regimen with the most favorable risk:benefit 
profile in these populations.
1.4. Risk/Benefit Assessment for the Study
As of January  2016,  Filgotinib has been administered to more than 150 healthy subjects as 
single doses ranging from 1 to 200 mg, and as multiple doses at 25 to 100 mg twice daily , and 
200, 300, and 450 mg dail yfor 10 day s. In addition, filgotinib has been administered to more 
than 1000 RA subjects and more than 150 subjects with Crohn’s disease at daily doses ranging 
from 50-200 mg. In general, filgotinib has been safe and well tolerated in all populations stu died.
Nonclinical studies in rats and dogs identified the test
esand lymphoid tissue as target organs for
filgotinib in long term repeat- dose toxicity  studies. In both species , histopathological changes in 
the testes included germ cell depletion and degene ration,with reduced sperm content and 
increased cell debris in the epididy mis and reduction in fertility  in rats. The dog was determined 
to be the most sensitive species. A dose of 200 mg/day of filgotinib resulted in an estimated 
mean clinical AUC of 2.80 μg ∙h/mL, which represents an exposure margin of 2.3, 1.8, and
3.4-fold when considering the mean AUC in male dogs at the NOEL in the 26 week and 39 week 
chronic toxicity  
studies, and the 39 week targeted exposure toxicity  study, respectivel y.
Decreased l ymphocytes observed in nonclinical studies have not been shown in clinical studies.
Filgotinib has shown an increased risk of embry ofetal malformations at exposures similar to 
human doses; the use of highl y effective contraception in the subject population is expected to 
mitigate this risk.
No clinically  relevant impact on cardiovascular parameters (including vital signs and E
CG), 
respiratory  or neurologic function has been observed in Phase 1 and 2 trials of filgotinib.  Across 
the phase 2 trials in RA, filgotinib was well -tolerated. I n the RA studies (including the open label 
extension Darwin 3), infections were reported more commonly  in the filgotinib groups, including 
serious infections leading to hospitalization, and even death. The most common sy stem organ 
classes (SOC) with AEs were infections and infestations, and gastrointestional disorders. Dose 
dependent decreases in the phase 2b studies were observed in mean neutro phil counts and 
platelet counts (but mean changes in both remained within normal laboratory  reference ranges), 
and there were no decreases in ly mphocytes or lymphocyte subsets. Hemoglobin levels slightl y 
improved (increased) with filigotinib treatment, con firming that no anemia was induced. Mild 
and clinically  insignificant serum creatinine increases were noted in both Phase 2b studies, with 
stabilization by  Week 24.  Neutrophil decreases (in the RA population) and a potential increased 
risk of infection ma y be considered risks consistent with the mechanism of JAK inhibition.  
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page29 05July2016Overall clinical findings and laboratory  changes are consistent with selective JAK 1inhibition 
and based on Phase 2 data the expected benefit of using filgotinib as proposed in this s tudy is 
considered to outweigh any  associated risks.
An independent data monitoring committee ( DMC)appointed to monitor the study  (with an 
interim safe ty analysis after the first 100 subjects complete 12 weeks of treatment) will provide 
an additional leve l of risk mitigation.The overall risk:benefit balance of this study  is considered 
favorable. For additional information about the risks of filgotinib, reference is made to the IB.
1.5. Compliance
This study  will be conducted in compliance with this protocol, Go od Clinical Practice (GCP), 
and all applicable regulatory  requirements.
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page30 05July20162. OBJECTIVES
The primary  objective of this study  is:
To evaluate the effects of filgotinib versus placebo for the treatment of signs and sy mptoms 
of rheumatoid arthritis (RA)as measured b y the proportion of subjects achieving an 
American College of Rheumatology  20% improvement response (ACR20) at Week12 
The secondary  objectives of this study  are: 
To evaluate the effects of filgotinib versus placebo for the treatment of sign s and symptoms 
of RA as measured b y the proportion of subjects achievin g Disease Activity  Score for 
28joint count using c-reactive protein (DAS28[CRP])≤3.2 at Week 12
To evaluate the effect of filgotinib versus placebo on phy sical function as measured by
change from Baseline in the Health Assessment Questionaire Disability  Index (HAQ -DI) at 
Week 12
To evaluate the safet y and tolerability  of filgotinib
To evaluate the effects of filgotinib on work productivity , fatigue, and general quality  of life 
as measured by SF-36, FACI T-Fatigue, EQ-5 and WPAI -RA.
The exploratory  objective of this study  is as follows: 
 
 
 
PPD
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page31 05July20163. STUDY DESIGN
3.1. Endpoints
The primary  endpoint is:
The proportion of subjects who achieve anACR20 response at Week 12.
The key secondary  endpoints are:
The proportion of subjects who achieve DAS28(CRP)≤3.2 at W eek 12
Change from Baselinein the 
HAQ-DI score at Week 12
Other secondary  endpoints are:
The proportion of subje cts who achieve ACR50 and ACR70 at Weeks 4, 12 and 24, ACR20 
at Weeks 4 and 24, and ACR20/50/70 over 
time from Day  1 through Week 24
Change from Baselinein individual components of the ACR response at Weeks 4,12, and
24and over time from Day  1through Week 24 
The proportion of subjects who achieve change in HAQ -DI of ≥0.22 at Weeks 4, 12, and 24, 
and over time from Day  1 through Week 24
Change from Baselinein DAS28 (CRP) at Weeks 4, 12, 24 and over time from Day  1
through Week 24
The proportion of subjects who achieve DAS28(CRP)≤3.2 at Weeks 4 and 24, and over time 
from Day  1 through Week 24
Theproportion of subjects who achieve DAS28(CRP)<2.6 at Weeks 4, 12, and 24, and over 
time from Day  1 through Week 24
ACR-N and EULAR  response at Weeks 4, 12, and 24, and over time from Day 1through 
Week 24 
Change from Baselinein CDAI at Weeks 4, 12, and 24, and over time from Day 1through 
Week 24 
Change from Baselinein SDAI at Weeks 4, 12, and 24, and over time from D ay 1through 
Week 24 
Absolute value and change from Baselinein SF-36, FACIT-
Fatigue,and the EQ -5D over 
time at Weeks 4, 12 and 24, and over time from Day  1through Week 24
Absolute value and change from Baselinein WPAI-RAat Weeks 4, 12, and 24, and over 
time from Day  1 through W eek24 
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page32 05July20163.2. Study Design
This isa randomized double-blind, placebo -controlled add-on Phase 3 study  in adult male and 
female subjects with moderatel y to severl y active RAdespite ongoing therapy  with 1 or 
2csDMARD (s)(ie,MTX, hydroxychloroquine, sulfasalazine, leflunomide) who have had an 
inadequate response or are intolerant to at least one biologic DMARD. The study  is designed to 
evaluate the efficacy , safety and tolerability  of filgotinib as well as its effect on patient
-reported 
outcomes, including work product ivity, fatigue, and quality  of life. In addition, PK will be 
assessed.
Adult male and female subjects with moderatel y to severly active RA will be screened to 
determine eligibility  as per the inclusion and exclusion criteria (see Section 4.2and 4.3, 
respectivel y). The Screening period will be up to 28 days .
Written informed consent must be obtained before any  study-related procedures take place. 
Subjects will be randomized in a 1
:1:1 ratio to filgotinib 200 mg, filgotinib 100 mg, or matching 
placebo controls for up to 24 weeks in a double- blind fashion.
At Week 14, subjects who have not achieved a 20% improvement from Day  1 in both swollen 
joint count (SJC) and tender joint count (TJC) will discontinue investigational therapy but will 
continue with study  visits and assessments per protocol. All subjects who discontinue from 
investigational therap y, are toreceive standard of care treatment for their RA as determined b y 
the investi gator. At Week 14, a ll subjects who achieve a 20% improvement from Day  1 in both 
SJC and TJC will remain on assigned therap y
through treatment Week 24.
At completion of the 24 -week treatment period, all subjects, regardless of response, will be 
offered the option to screen for a Long T erm Extension ( LTE)study (GS-US-417-0304).
For those subjects not entering the LTE, a follow -up visit will be completed at Post Treatment 
Week 4. 
To enhance the safe ty monitoring during the study, a data monitoring committee (DMC) 
consisting of independent experts will be convened to periodically  review the accumulating 
safety data for the stud y. In addition, a cardiovascular safet y endpoint adjudication committee 
(CV-SEAC) will be convened to periodically  review and adjudica te all possible major 
cardiovascular events (MACE).
The assessments planned to be performed at each visit are detailed in the study  procedures table 
(Appendix 2). A schedule of the stud y design is provided below.
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page33 05July2016Figure3-1. Study Design
3.3. Study Treatments
Approximately  423subjects will be randomized in a 1:1 :1ratio to filgotinib 200 mg q.d.,  
filgotinib 100 mg q.d. , orplacebo control group for up to 24weeksas follows
, all subjects will 
be on a stable dose of permitted csDMARD(s) : 
Filgotinib 200 mg group: filgotinib (200 mg once daily  [q.d.]) +  placebo to match filgotinib 
100 mg (PTM q.d.) .) (N=141) 
Filgotinib 100 mg group: filgotinib (100 mg q.d.) + placebo to match filgotinib 200 mg 
(PTM q.d.) (N=141) 
Placebo control group: placebo to match filgotinib 200 mg  and placebo to match filgotinib 
100mg (PTM q.d.) (N=141) 
NOTE: on study  visit days, subjects should wait to take their regularl y scheduled dose of stud y 
drug until instructed b y site personnel, in case there are pre -dose blood draws or other pre -dose 
procedures required on that day .
3.4. Duration of Treatment
Subjects are planned to participate in the stud y for approximately  32 weeks (from Screening visit 
to Follow-up vi sitor entry into the LTE); the duration of 
dosing is up to 24 weeks.

Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page34 05July20163.5. Criteria for Interruption or Discontinuation of Study Treatment
3.5.1. Study Drug Interruption C onsiderations
The Gilead Medical Monitor should be consulted prior to study  drug interruption when 
medically  feasible. 
Study drug interruption should be considered in the following circumstances; prior to resumption 
of study drug, the investigator should discuss the ca
se with the Gilead medical monitor :
Intercurrent illness that would, in the judgment of the investigator, affect assessments of 
clinical status to a significant degree.   
Subject is scheduled for elective or emergency  surgery (excluding minor skin procedu res 
under local or no anesthesia); timing of study  drug pausing should be determined in 
consultation with the Gilead medical monitor.    
Any subject who develops a new infection during the study  should undergo prompt and 
complete diagnostic testing appropr iate for an immuncompromised individual , and the 
subjectshould be closel y monitored.
NOTE: During the time of study drug interruption for any of the above, the subject may 
continue to have study visits and to take part in procedures and assessments, if de emed 
medically appropriate by the investigator.
3.5.2. Study Drug Discontinuation C onsiderations
The Gilead Medical Monitor should be consulted prior to study drug discontinuation when 
medically  feasible. 
Study medication 
shouldbe permanently  discontinued in the following instances:
Any opportunistic infection
Any seriousinfection that requires antimicrobial therap y or hospitalization, or an y infection 
that meets SAE reporting criteria. 
Complicated herpes zoster infection (with multi- dermatomal, disseminate d, ophthalmic, or 
CNS involvement)
Evidence of active HCV during the stud y, as evidenced b y HCV RNA positivity
Evidence of active HBV during the stud y, as evidenced b y HBV DNA positivity
Unacceptable toxicity , ortoxicity that, in the judgment of the inves tigator, compromises the 
subject’s ability  to continue study -specific procedures or is considered to not be in the 
subject’s best interest
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page35 05July2016Non-responder at Week 14 as outlined in Section 3.2
Subject request to discontinue for an y reason
Subject noncompliance
Pregnancy  during the study  (Section 7.7.2.1and Appendix 5)
Discontinuation of the study  at the request of Gilead, a regulatory  agency or an institutional 
review board or independent ethics committee (IRB/IEC)
Subject use of prohibited concur rent therap y maytrigger study  drug discontinuation; 
consultation should be made with the Gilead medical monitor.
Laboratory  criteria:
After becoming aware of any  of the belowdescribed abnormal laboratory  changes occurring at 
any one time, an unscheduled visit (ie sequential visit) shouldoccur to retest within 3 to 7 days
(except creatinine, which should be retested 7 -14 days apart). 
2sequential neutrophil counts <750 neut rophils/mm3(SI: <0.75x109cells/L) 
2 sequential platelet counts <75,000 platelets/mm3(SI: <75.0x109cells/L)
2sequential AST or ALT elevations >3xUL N and ≥1 total bilirubin value >2xULN or
accompanied b y symptoms consistent with hepatic injury .1
2sequential AST or ALT elevations >5xUL N
2sequential values for e stimated creatinine clearance < 35mL/min based on the Cockroft 
Gault formula
Subjectswhopermanently discontinue studymedication foranyreasonaretoreceivestandardof
caretreatment fortheirRAasdetermined bytheinvestigator ,andthosesubjectsshouldbe
encouraged tocontinuestudyvisitsandprocedures, ifdeemedmedically appropriate bythe
investigator . Subjects whopermanentl ydiscontinue studymedication for  pregnancy shouldnot
continueinthestudy;ifthereareanyquestions regarding permanent discontinuation, these
shouldbediscussed withtheSponsor.
                                                
1In each case, there is a need for additional investigations, such as review of ethanol, recreational drug and dietary 
supplement consumption; testing for acute hepatitis A, B or C infection and biliary tract imaging should be pro mptly 
discussed with the s tudy Medical M onitor
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page36 05July2016Subjectswithdrawing fromthestudyshouldcomplete ETandPostTreatment Week4 visits.
Subjectsarefreetowithdraw fromthestudyatanytimewithoutproviding reason(s) for
withdrawal andwithoutprejudice tofurthertreatment. Thereason(s) forwithdrawal willbe
documented intheelectronic casereportform(eCRF).
Reasonable eff orts will be made to contact subjects who are lost to follow -up. All contacts and 
contact attempts must be documented in the subject’s file.
The Sponsor has the right to terminate the study  at any time in case of safety  concerns or if 
special circumstances concerning the stud y medication or the compan y itself occur, making 
further treatment of subjects impossible. I n this event, the investigator(s) and relevant authorities 
will be informed of the reason for stud y termination.
3.6. End of Study
End of Study  is defined as when the last subject has completed 24 weeks of dosing plusthe
4weekpost treatment or has entered the LTE. 
3.7. Post Study Care
All subject s, 
regardless of respose whocomplete 24 weeks of study  assessments 
will be offered 
an opportunity  to participate in an LTEstudy (GS-US-417-0304).Subjectswho discontinue 
early from the main study, or discontinue from study  treatment due to toxicity are not eligible for 
the LTE study, and should have a Post -Dosing Visit, 4 weeks after the last dose of study  drug. 
The long term care of subjects who do not qualify or choose not to participate in the LTE will 
remain the responsibility  of their primary  treating phy sician. 
3.8. Biomarker 
Samples
3.8.1. Biomarker Samples to Address the Study Objectives
 
 
 
 
PPD
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page37 05July2016The biomarker sample collection schedule is described in Study  Procedures Table (Appendix 2). 
Sincebiomarker science is a rapidly  evolving area of investigation, it is not possible to specify  
prospectivel y all tests that maybe performed on the specimens collected.  The testing outlined 
above is based upon the current state of scienti fic knowledge. It may  be modified during or after 
the end of the stud y to remove tests no longer indicated and/or to add new parameters based 
upon the growing state of art knowledge. An y future testing of new tests not described above 
must be approved b y local authorities as applicable according to specific local regulations.
 
 
 
For sampling procedures, storage conditions, and shipment instructions, see the Sample Handling 
and Logistics Manual. 
3.8.2. Biomarker Samples for Optional Future Research
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PPD
PPD
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page38 05July2016 
3.8.3. Biomarker Sam ples for Optional Genomic Research
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PPD
PPD
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page39 05July20163.9. SUBSTUDY: 
 
 
 
PPD
PPD
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page40 05July20164. SUBJECT POPULA TION 
4.1. Number of Subjects and Subject Selection
A sufficient number of subjects will be screened to ensure that approximately  423subjects with 
moderatelyto severely activeRAare randomized to 1 of 3 dosing groups.
4.2. Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for participation in this 
study.
1)Male or female subjects who are ≥18 years of age, on the day  of signing informed consent. 
2)Have a diagnosis of RA ( 2010 ACR/EUL AR criteria for RA ) (Appendix 8
), and are ACR 
functional class I -III.
3)Have ≥6swollen joints (from a SJC66) and ≥6tender joints (from a TJC68) at bothscreening 
and Day 1(need not be the same joints) (Appendix 7
)
4)Have serum CRP ≥4 mg/L.
5)Ongoing treatment with a stable
presecription of 1 or2 csDMARD (s)as follows: 
Permitted csDMARD (s
)
a)Use of MTX for at least 12 weeks prior to Day  1. Subject is on a stabl y prescribed dose 
and route of administration of 7.5-25 mg/weekl y for at least 4 weeks prior to Day  1. 
Stable weekl y doses <7.5 mg are allowed onl y in the presence of intolerance to or 
toxicity from higher doses or where higher doses are prohibited b
ythe local label or local 
clinical practice. Doses >25 mg weekl y are not permitted.  
b)Subjects on MTX should be receivingan adequate and prescribed stable dose of foli c 
acid (≥5mg/week total dose or as per local clinical practice) which should be confirmed 
or initiated at Screening, and continued throughout the study . 
MTX is not permitted to be used in combination with leflunomide
c)Oral hydroxychloroquine ≤400mg/day or chloroquine ≤250mg/day with prescription
having been stable for at least4 weeks prior to Day 1
d) Oral sulfasalazine 1 g to 3g/day with prescription having been stable for at least4weeks 
prior to Day 1
e)Oral leflunomide 10 -
20mg/day with prescription having been stable for at least4weeks 
prior to Day 1  
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page41 05July2016The treatment with csDMARD (s)should be continued at a stable dose until the end of the 
study. Dose adjustments are onl y permitted for the management of toxicity . Prior treatment 
with additional csDMARDs is allowed, however, subject may  only be on 1 or 2 csDMARDs 
at Day 1 and appropriate wash out needs to be satisfied according protocol (Section 5.3), in 
order to be eligible for the study .
6) Have received at least one bDMARD for the treatment of RA to w hich they have had an 
inadequate response or intolerance. An inadequate response is defined as documented 
continued or recurrent disease activity  after at least 12 weeks of treatment with any  
investigational or licensed bDMARD, including biosimilars, for t he treatment of  RA.
Intolerance is defined as any documented adverse effect associated with 
a  bDMARD used 
according to its respective label. There is no limit to the prior number of bDMARDs that may  
have been used b y the subject, however, the subject mus t not be on a bDMARD at Day  1 
(appropriate wash out needs to be satisfied according to the protocol) or during the study .
7)Females of childbearing potential (defined in Appendix 5) must have a negative pregnancy  
test at screening and Day 1 
8)Male subjects and female subjects of childbearing potential who engage in heterosexual 
intercourse must agree to use protocol specified method(s) of contraception as described in 
Appendix 5
9)Lactating femalesubjectsmustagreetodiscontinue nursingfromScreeningthroughtheend
oftheirstudyparticipation
10)Meet one of the following tuberculosis (TB) Screening criteria : 
a)No evidence of active or latent TB, 
A negative QuantiFERON®TB-Gold In-Tube test at Screening and 
Achest radiograph (views as per loc al guidelines) taken at Screening or within the 
3
months prior to Screening (with the report or films available for investigator 
review) without evidence of active or latentTB infection and
No history  of either untreated or inadequatel y treated latent or active TB infection
b)Previously  treated for TB 
ieif a subject has previously  received an adequate course of 
therapy as per local standard of care for either latent TB(9months of isoniazid i n a 
location where rates of primary  multi-drug resistant TB infections are <5% or an 
acceptable alternative regimen) or active TB (acceptable multi -drug regimen). In these 
cases, no QuantiFERON®TB-Gold In-Tube test or equivalent assay  need be obtained, 
but a chest radiograph must be obtained if not done so within 3 months prior toScreening
(with the report or films available for investigator review) . It is the responsibility  of the 
investigator to verif y the adequacy  of previous anti -tuberculosis treatmen t and provide 
appropriate documentation.
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page42 05July2016c)Newly identified latent TB during screening ie, a subject who has a newl y identified 
positive diagnostic TB test result (defined as a positive QuantiFERON®TB Gold in Tube 
test [or equivalent assay ]) in which active TB has been ruled out and for which 
appropriate , ongoing, prophy lactictreatment for latent TBhas been initiated prior to the 
first administration of study  medication. Adequate treatment for latent TB is defined 
according to local country  guidelines for immunocompromised subjects.
Cases falling under category  “b” and “c” need to be approved b y the Sponsor prior to  
enrollment in the study . No subject with currently ACTIVE TB may  be enrolled in the study , 
regardless of past or present anti- TB medication use.
11)Able and willing to sign the informed consent as approved b y the IRB/IEC. Written consent 
must be provided before initiating an y screening evaluations. Subjects must have read and 
understood the ICF, must fully  understand the requirements of the study , and must be 
willing to comply  with all study  visits and assessments subjectswhocannotreador
understand theICFmaynot beenrolledbyaguardianoranyotherindividual .
12)Subjects receiving non -prohibited medication for any  reason should 
be on a stable dose 
(defined as no change in prescription ) within 7 days or 5half-lives (whichever is longer) 
prior to the first administration of study  drug on Day  1.
4.3. Exclusion Criteria
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study .
1)
Prior treatments for RA as follows:
a)Alkylating agents, ie , chlorambucil or cy clophosphamide, at any  time
b) Previous treatment with JAK inhibitor 
c)Leflunomide use within 8 weeks prior to Day  1 or in the case of cholest yramine washout, 
within 4weeks prior to Day  1
d) Discontinuation of hydroxyxhloroquine or chloroquine less than 4 weeks prior toDay 1.
e)Cyclosporine, other calcineurin inhibitors, gold therap y, mycophenolate , or azathioprin e 
within 4weeks prior to Day 1
f)B-cell depleting agents ( ie, rituximab) within 6 months prior to 
Day 1.Documentedreturn 
of CD19 cell srequiredfor subjectswho have received B -cell depleting agent (s)
. 
g)Use of non-cell depleting bDMARDs, including: a batacept, adalimumab, certolizumab 
pegol, golimumab, infliximab, tocilizumab , anakinra or etanercept (including biosimilars) 
within 4weeks prior to Day 1.
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page43 05July20162)Known hy persensitivity  or allergy  to the study  drug, its metabolites, or formulation 
excipients.
3) Oral steroids at a dose >10 mg/day of prednisone equivalent or a prescription for oral steroids 
which has changed within 4 weeks of Day 1.
4)Receipt of an intra -articular or parenteral corticosteroid injection within 4 weeks prior to 
Day1.
5)Use of nonsteroidal anti -inflammatory  drugs (NSAID (
s) which have not been at a stable dose 
(defined as no change in prescription) for at least 2weeks prior to 
Day 1. NOTE:subjects are 
permitted to take acet ylsalicylic acid at a dose of ≤325mg daily for cardiac proph ylaxis, or 
occasional NSAIDs for non-R A indications (eg. headache) .
6)Administration of a live / attenuated vaccine within 30 daysprior toDay 1, or planned during 
the study.
7)Participation in any  clinical study  of an investigational drug/device within 4 weeks or 
5half-lives prior to Screening, whichever is longer. Exposure to investigational biologics 
should be discussed with the sponsor.
8)
Have undergone surgical treatments for RA including s ynovectomy orarthroplasty  in 
>4joints and/or within the last 12 weeks prior to Screening 
9)Haveanychronic,uncontrolled medicalcondition, whichwould
putthesubjectatincreased
riskduringstudyparticipation, suchasuncontrolled: diabetes, hypertension, morbidobesity,
thyroid,adrenal,pulmonary ,hepatic,renal,neurologic orpsychiatricdisease,or
otherdiseaseofconcern,asperjudgment of investigator
10)Have a history  of major surgery  (requiring regional block or general anesthesia) within the 
last 12weeks prior to Screening or planned major surgery during the study .
11)Have a moderate ly to severel y active, generalized musculoskeletal disorder that would 
interfere with assessment of study  parameters or increase risk to the subject by  participating 
in the study , eg, generalized osteoarthritis, sy stemic inflammatory  condition other than R A 
such as, but not limited to: ankylosing spondy litis, reactive arthritis, psoriatic arthritis, 
inflammatory  bowel disease associated arthropathies, sy stemic lupus ery thematosus, 
scleroderma, inflammatory  myopathy, mixed connective tissue disease, overlap syndrome, or 
gout. Subjects with an y history of Felty’s syndrome or juvenile idiopathic arthritis are 
excluded, regardless of the disease activity  level at Screening. (NOTE: subjects with 
concurrent Sjogren's s yndrome or limited cutaneous vasculitis associated with RA are not 
excluded, and may  be enrolled, based on investigator judgment).
12)Active autoimmune disease other than those listed above, that would interfere with 
assessment of study  parameters or increase risk to the subject by  participating in the study, 
eg, inflammatory  bowel disease, uncontrolled th yroiditis, sy stemic vasculitis, transverse 
myelitis or uveitis.
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page44 05July201613)History of or current moderate to severe congestive heart failure (New York Heart 
Association [NYHA] class III or IV), or within the last 6 months, a cerebrovascular accident, 
myocardial infarction, unstable angina ,unstable arrhy thmia or new or significant ECG 
finding at Screening, or any other cardiovascular condition which, in the opinion of the 
investigator, would put the subject at risk by participation in the study .
14)History of malignancy  within the past 5 years prior to Screening (except for adequatel y 
treated basal cell carcinoma or non -metastatic squamous cell carcinoma of the skin or 
cervical carcinoma in situ with no evidence of rec urrence).
15)History of lymphoproliferative disease or current ly mphoproliferative disease. 
16)History of gastrointestinal perforation.
17)History of organ 
or bone marrow transplant.
18)Positive serology  for human immunodeficiency  virus (HIV)1 or 2
19)Evidence of active Hepatitis C Virus (HCV) infection. Subjects with positive HCVAb at 
screening, require reflex testing for HCV RNA. Subjects with positive Hep C RNA viral 
load (VL) at screening will be excluded. Subjects with positive HCV Ab, but negative HCV 
RNA VL are eligible per investigator judgment, but require ongoing monitoring as outlined 
in the schedule of assessments [NM1]. Subject with  active HCV during the study , as 
evidenced b y RNA positivity ,will be discontinued 
from study  drug as outlined in the 
protocol.
20)Evidence of active Hepatitis B Virus (HBV) infection. Subjects with positive HBV 
surfaceantigen (HBsAg) at screening are excluded from the study. Subjects with positive 
HBV core Ab and negative HBsAg, require reflex testing for HBV DNA. Subject
s with 
positive HBV DNA at screening will be excluded. Subjects with positive HBV core Ab, and 
negative HBV DNA are eligible per investigator judgment, but may  require prophy lactic 
treatment in accordance with HBV treatment guidelines/local standard of car e and require 
ongoingmonitoring with blood tests for HBV DNA every  3 months, as outlined in the 
schedule of assessments. Subject with evidence of active Hepatitis B during the study ,as 
evidenced b y DNA positivity , will be discontinued from study  drug asoutlined in the 
protocol.
21)History of opportunistic infection or immunodeficiency  syndrome which would put the 
subject at risk, as per investigator judgment.
22)Active infection that is clinically  significant, as per judgment of the investigator, or any  
infection requiring hospitalization or treatment with intravenous anti -infectives within 60 
days of Screening; or any infection requiring oral anti -infective therap y within 30 days of 
Screening.
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page45 05July201623)Currently  on any therapy for chronic infection (such as pneumoc ystis, cytomegalovirus, 
herpes zoster, and aty pical mycobacteria). Past history  of disseminated Staphy lococcus 
aureusor disseminated Herpes simplex infection. 
24)History of symptomatic herpes zoster infection within 12 weeks prior to S creening or have 
history of disseminated/complicatedherpes zoster infection (multi
-dermatomal involvement, 
ophthalmic zoster, central nervous sy steminvolvement or postherpetic neuralgia).
25)History of an infected joint prosthesis or other implanted device with retention of the 
prosthesis or device in situ.
26)Currentdrug, tobacco or alcohol abuse per investigator judgment .
27)Any condition including active fibrom yalgia that based on the investigator’s opinion would 
make it difficult to appropriately  assess RA activity  for the purpose s of this study . 
28)Any condition or circumstances which in the opinion of the investigator or Sponsor may  
make a subject unlikel y or unable to complete the study or compl y with study  procedures and 
requirements.
29)Significant blood loss (>450 mL) or transfusi on of any  blood product within 12 weeks prior 
to Day 1.
30)Use of prohibited medication as outlined in Section 5.3
31)Tests performed at the central laboratory  at Screening 
that meet any  of the criteria below
(outof range lab values may  be rechecked one time, after consultation with the sponsor or 
it’s designee , before subject is considered a screen -failure):
a)Hemoglobin <8.0 g/dL (International Sy stem of Units [SI ]: <80g/L);
b) White blood cells <3.0 x 103cells/mm3(SI: <3.0 x 109cells/L);
c)Neutrophils <1.5 x 103cells/mm3(SI: <1.5 x 109cells/L);
d)Lymphocytes <0.5 x 103cells/mm3(SI: <0.5 x 109cells/L);
e)Platelets <100 x 103cells/mm3(SI: <100 x 109cells/L);
f)Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥1.5 x ULN;
g)Total bilirubin level ≥2 x ULN unless the subject has been diagnosed with Gilbert’s  
disease and this is clearly documented 
h)Estimated creatinine clearance <40 mL/min based on the Cockroft Gault formula 
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page46 05July20165. INVESTIGA TIONAL  MEDICINAL PRODUCTS
5.1. Randomization, Blinding and Treatment Codes
An Interactive Web Response Sy stem (IWRS) will be employ ed to manage subject 
randomization and treatment assignments . It is the responsibility  of the investigator to ensure that 
the subject is eligible for the study  prior to en rollment. Subjects will be assigned a Screening 
number at the time of consent. 
5.1.1. Procedures for Breaking Treatment Codes
In the event of a medical emergency  where breaking the blind is required to provide medical care 
to the subject, the investigator may  obtain the individual subject treatment assignment directly 
from the I WRS system.Gilead recommends but does not require that the investigator contact the 
GileadMedical Monitor before breaking the blind. Treatment assignments should remain blinded 
unless that knowledge is necessary  to determine emergency  medical care for the subject . The 
rationale for unblinding must be clearl y explained in source documentation and on electronic 
case report form (eCRF), along with the date on which the treatment assignment was 
unblinded. The investigator is requested to contact the Gilead Medical Monitor promptly  in case 
of any treatment unblinding .
Blinding of stud y treatment is critical to the integrity  of this 
Phase 3 clinical trial and ther efore, if 
a subject’s treatment assignment is disclosed to the investigator, the subject will have study  
drug
discontinued. 
GileadDrug Safet y and Public Health (DSPH) may independentl y unblind cases for expedited 
reporting of suspected unexpected serious adverse reactions (SUSARs) to Regulatory  
Authorities.
5.2. Description and Handling of Filgotinib and PTM Filgotinib
5.2.1. Formulation of Filgotinib and PTM Filgotinib
Filgotinib is provided as100mg and 200 mg strength tablets. Fi lgotinibtablets, 100 mg and 
200 mg tablets,are 
beige,debossed with “GSI” on one side and “100” or “200” on the other , 
capsule-shaped, biconvex, film -coated tablets for clinical use. Each tablet contains the equivalent 
of 100 mg or 200 mg filgotinib free base in the form of filgotinib maleate. In addition to the 
active ingredient, filgotinib tablets contain the following inactive ingredients: microcry stalline 
cellulose, lactose monohy drate, fumaric acid, pregelatinized starch, silico n dioxide, magnesium 
stearate, macrogol/PEG 3350, poly vinyl alcohol, talc, titanium dioxide, iron oxide y ellow,and 
iron oxide red.
Placebo to match filgotinib tablets, 100 mg and 200 mg, areidentical in appearance to the 
respective active tablets . Placebo to match filgotinib tablets contain the following inactive 
ingredients: microcry stalline cellulose, lactose monohy drate, croscarmellose sodium, magnesium 
stearate, macrogol/PEG 3350, poly vinyl alcohol, talc, titanium dioxide, iron oxide y ellow, and 
iron oxide red.
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page47 05July20165.2.2. Packaging and Labeling
Filgotinib tablets, 100 mg and 200 mg, and PTM filgotinib tablets, 100 mg and 200 mg, are 
packaged in white, high density  polyethylene (HDPE) bottles. Each bottle contains 30 tablets, 
silica gel desiccant and poly ester packing material. Each bottle is enclosed with a white, 
continuous thread, child -resistant poly propylene screw cap fitted with an induction- sealed and 
aluminum -faced liner . 
Sufficient quantities of filgotinib tablets,100 mg and 200 mg , and PTMfilgotinib tablets, 
100 mg and 200 mg, to complete the entire study  will be shipped to the investigator or qualified 
designee from the Gilead Supply  Management Team (or its designee).
Study drugs to be distributed to participating centersin the US and other particip ating countries
shall be labeled to meet applicable requirements of the United States Food and Drug 
Administration (FDA), theEU Guideline toGood Manufacturing Practice -Annex 13 
(Investigational Medicinal Products) and/or other local regulations, as app licable. 
5.2.3. Storage and H
andling
Filgotinib tablets and PTM filgotinibtablets should be stored at controlled room of 25°C(77F); 
excursions are permitted between 15 Cand30C (59Fto86F).
Storage conditions are specified on the label. Until dispensed to the subjects, all drug products 
should be stored in a securely  locked area, accessible only  to authorized site personnel. To 
ensure the stability  of the study  drug and to ensure proper product identification, the drug 
product should not be stored in a c ontainer other than the container in which they  are supplied. 
Consideration should be given to handling, preparation, and disposal through measures that 
minimize drug contact with the body . Appropriate precautions should be followed to avoid direct 
eye contact or exposure when handling .
5.2.4. Dosage and Administration 
Filgotinib tablets, 100 mg and 200 mg,and PTM filgotnib tablets, 100 mg and 200 mg, will be 
administered once daily  with or without food. Each subject shouldbe given instructions to 
maintain app roximately  the same dail y time of administration to ensure similar dosing interval is 
maintained between study  drug doses.
For missed dose(s) of study medication, subjects should be instructed to take the missed 
dose(s)of study medication as soon as poss ible during the same day . If the missed dose is not 
taken on the original day
, subjects should be cautioned not to double the next dose with the 
missed dose of study  drug under an y circumstances. In those cases, the missed dose should be 
returned to the st udy drug bottle
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page48 05July20165.3. Prior and Concomitant Medications
Concomitant therapies taken for treatment of pre- existing conditions can continue during the 
study provided they  are in accordance with the inclusion and exclusion criteria (see Section 4.2
and 4.3). It is preferred that these medications be continued without variation of dose or regimen 
during the stud y, as much as possible .All non-RA medication use d within 30 day s of consent
(including an y changes) is to be documented in the eCRF.All prior medication used for
treatment 
ofRA, are to be documented in the eCRF. 
At each study visit, the site will capture an y and all medications taken b y the subject since the 
last visit or during the visit (as applicable). Concomitant medications in clude prescription, non -
prescription medications, therapies, dietary  supplements, and minerals.
In case new (non -prohibited) therapies need to be administered during the study , the risk/benefit 
to the subject should be carefull y assessed and consideration given to the timing of an y necessary  
introduction of new medications. 
As specified in the inclu sion criteria, eligible subjects must be on a stable dose of 1 to 
2csDMARD (s)andshouldremain on that stable dose until the end of the study :
MTX on a continuous basis for ≥12 weeks prior to Day  1 and on a stabl y prescribed dose and 
route of administra tionbetween 7.5 and 25 mg/weeklyfor at least 4 weeks prior to Day  1. 
Stable weekl y doses <7.5 mg are allowed onl y in the presence of intolerance to or toxicity  
from higher doses or where higher doses are prohibited by the local label or local clinical 
practices.  Doses >25 mg weekl y are not permitted.  Subjects on MTX should be receiving an 
adequate and stable dose of folic acid ( ≥5 mg/week total dose or as per local clinical practice) 
which should be confirmed or initiated at Screeni ng, and continued throughout the study .  
Oral hydroxychloroquine ≤400mg/day or chloroquine ≤250mg/day with prescription having 
been stable for at least 4weeks prior to 
Day 1
Oral sulfasalazine 1g to 3g/day with prescription having been stable for at least4weeks 
prior to Day 1
Oral leflunomide 10 -20mg/day with prescription having been stable for at least 12 weeks 
prior to Day 1  
Note that MTX is not permitted to be used in combination with leflunomide. Permitted 
concomitant medications should be kept stable for the study  duration, as much as possible, and
include:
NSAIDs, at a stable dose and regimen, as much as possible; NSAI D doses should be held 
starting
12hours before a study  visit until after all scheduled assessments have taken place, 
as much a s possible
Oral steroids ≤10 mg/day prednisone or equivalent, provided that the prescription has been 
stablefor at least 28 day s prior to Day  1 
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page49 05July2016Analgesics, including opioids and other non -NSAID based therapies, at a stable dose and 
regimen, as much as possible; analgesic doses should be held starting 12 hours before a study  
visit until after all scheduled assessments have taken place, as much as possible
Dose adjustments for management of toxicity of the above medications are allowed and 
should be documented, along with documentation of the AE which led to the change in the 
medication
Female subjects of childbearing potential must agree to use highl y effective birth -control 
methods as outlined in Appendix 5and must agree to continue their use during the stud y and for 
at least 35daysafter the last dose of study  medication. The use of hormonal contraceptives will 
be recorded in the Concomitant Therap y section of the eCRF. Applicable procedures and 
treatment guidance based on package i
nserts will be followed
. 
Hormone replacement therap y,thyroidreplacement and other chronic therapies (such as those 
for well-controlled diabetes or hy pertension) are permitted during the study, and should be kept 
at a stable dose and regimen, as much as possible.
Vitamin, mineral or herbal supplementations are permitted during the study per judgment of 
investigator , and should be kept at a stable dose and regimen, as much as possible .
Prohibited concomitant medications(and their wash out period as applic able) while on study  
drugsinclude: 
Any DMARDs, other than the ones specified above,
Oral or injectable gold within 4weeks prior to Day 1
Azathioprine within 4weeks prior to Day  1
D penicillamine within 4 weeks prior to Day  1
Cyclosporine within 8 weeksprior to Day  1
Any cytotoxic agent, including chlorambucil, cy clophosphamide, nitrogen mustard, and other 
alkylating agents.
Use of an y other JAK inhibitor or other small molecule immunomodulator
Any injectable corticosteroids and receipt of an intra-articular or parenteral cortcosteriod 
injection within 4 weeks prior to Day  1 is prohibited.
Potent Pg-p inducers (e.g. rifampin, phen ytoin, carbamazepine, and St. John’s wort)within 
3weeks prior to Day  1
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page50 05July2016Previous treatment at an y time with a cytotoxic agent, other than MTX, before Screening is 
prohibited. 
Previous use of JAK inhibitors is prohibited.
Receipt of an intra -articular or parenteral corticosteroid injection within 4 weeks prior to Day  1
and forthe duration of the study  is prohibited.
For subjects who are treated with isoniazid, consideration should be given to supplementation 
with vitamin B6 (py ridoxine) to reduce the risk of peripheral neuropath y.
Vaccine Guidelines:
Prior to study  participat ion, it is recommended that the subject’s vaccinations be brought up 
to date according to local vaccination standards.
Live or attenuated vaccines (including, but not limited to varicella and inhaled flu vaccine) 
are prohibited within 30 day s of Day1, throughout the study , and for 6 weeks after the last 
dose of study  drug.
Subjects should be advised to avoid routine household contact with persons vaccinated with 
live/attenuated vaccine components. General guidelines suggest that a study subject’s 
exposure to household contacts should be avoided for the below stated time periods:
Varicella or attenuated typhoid fever vaccination – avoid contact for 4 weeks following 
vaccination
Oral polio vaccination --avoid contact for 6 weeks following vaccination
Attenuated rotavirus vaccine --avoid contact for 10 day s following vaccination
Inhaled flu vaccine --avoid contact for 1 week following vaccination
Inactivated vaccines (such as inactivated flu vaccines) should be administered according to local 
vaccination sta ndards whenever medicall y appropriate; however, there are no available data on 
the concurrent use of filgotinib and its impact on immune responses following vaccination.
5.4. Accountability for Study Drugs
The investigator is responsible for ensuring adequate a ccountability  of all used and unused study 
drugs. This includes acknowledgement of receipt of each shipment of study drugs(quantity and 
condition). All used and unused study drugsdispensed to subjects must be returned to the site.
Filgotinib accountabili ty records will be provided to each study  site to:
Record the date received and quantity  of study drugs
Record the date, subject number, subject initials, the study drugnumber dispensed
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page51 05July2016Record the date, quantity of used and unused study drugsreturned, along with the initials of 
the person recording the information. 
Dispensing records will include the initials of the person dispensing the study  drug or 
supplies.
5.4.1. Investigational Medicinal Product Return or Disposal
At study initiation, the monitor will evaluate the site’s standard operating procedure for 
investigational medicinal product disposal/destruction in order to ensure that it complies with 
Gilead’s requirements. Study  drug may  be returned or destro yed on an ongoing basis during the 
study if appropriate. At the end of the stud y, following final drug inventory reconciliation b y the 
monitor, the study  site will dispose of and/or destroy  all unused investigational medicinal 
product supplies, including empt y containers, according to these procedures. If the site cannot 
meet Gilead’s requirements for disposal, arrangements will be made between the site and 
Gilead’s or its representative for destruction or return of unused investigational medicinal 
product supplies.
All drug supplies and ass ociated documentation will be periodically  reviewed and verified by  the 
study monitor over the course of the study .
For additional information about study  drug accountability  and return, refer to Section 9.1.7. 
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page52 05July20166. STUDY PROCEDURES
The study  procedures to be conducted for each subject enrolled in the study  are presented in 
tabular form in Appendix 2and described in the text that follows. Additional information is 
provided in the study  procedures manual and Appendix 11.
The investigator must document an y deviation from protocol procedures and notify  the sponsor 
or contract research organization (CRO).
The study  assessments as described below will be performed at the time points specified in the 
Study Procedures Table ( Appendix 2).Visits are to be scheduled wit hin a window as specified in 
the Study  Procedures Table and in such a way  that the total study  duration from Day 1to last 
dosing does not exceed 24weeks,as much as possible
6.1. Subject Enrollment and Treatment Assignment
Subject eligibility  will be established at the conclusion of the screening evaluations. The 
screening number and subject ID will be assigned for each subject b y IWRS.
It is the responsibility  of the investigator to ensure that each subject is eligible for the study  
before before ran domization. A subject will be considered enrolled once randomized.
6.2. Pretreatment Assessments
6.2.1.
Screening Visit
Subjects will be screened within 28 days before randomization to determine eligibility for 
participation in the study . Subject-reported outcomes, in cludingGlobal Assessment, HAQ- DI 
and Pain Scale are recommended to be done before an y other stud y procedures. Invasive stud y 
procedures such as blood draws should be done at the end of a stud y visit, as much as possible . 
The following will be performed an d documented at screening:
Obtain written informed consent
Subject 
global assessment
HAQ-DI and Pain Scale
Obtain demographics and medical history (including onset of RA, 
disease characteristics, 
smoking habits, average weekl y alcohol consumption, and family  history of coronary  heart 
disease)
Complete physical examination ,including height
Weight
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page53 05July2016Vital Signs
Perform SJC66/TJC68
12-Lead ECG
Physician’s global assessment
Obtain blood samples for :
Serology
Hematology  and Serum Chemistry
Serum CRP
Serum pregnancy  test (if applicable)
Rheumatoid factor, anti- CCPAb
FSH (females only), TSH, HbA1c
Quantitative immunoglobulin (Ig)
Urinalysis
TB test and Chest X -ray (if applicable)
Review and collection of concomitant medications
Record an y serious adverse events and all adverse events related to protocol mandated 
procedures occurring after signing of the consent form.
Subjects meeting all of the inclusion criteria and none of the exclusion criteria will return to the 
clinic after screening for randomization into the study . 
Subjects who do not meet the eligibility  criteria will be excluded from randomization and may  be 
considered for rescreening one time for the stud y in consultation with the Sponsoror its 
designee.
From the time of obtaining informed consent t hrough the first administration of investigational 
medicinal product, the investigative site is to record all serious adverse events (SAEs), as well as 
any adverse events related to protocol-mandated procedures on the adverse events case report 
form (CRF/eCRF).  All other untoward medical occurrences observed during the screening 
period, including exace rbation or changes in medical history  are to be captured on the medical 
history CRF/eCRF.  See Section 7 Adverse Events and Toxicity  Management for additional 
details.
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page54 05July20166.2.2. Day 1 Assessments
At Day 1, after the subject’s eligibility  for the study  has been confirmed, the subject will be 
randomized into the study  to receive one of three dosing regimens.
Subject’s Global Assessment, HAQ- DI and Pain Scale, FACIT -Fatigue, SF -36 are recommended 
to be completed before any  other stud y procedures. I nvasive study  procedures such as blood 
draws should be done at the end of a stud y visit. The following will be performed and 
documented at Day 1prior to dosing
Subject global assessment
HAQ-DI and Pain Scale
FACIT-Fatigue, SF-
36
WPAI-RA, EQ- 5D, where available

TSQM,when and where available
Healthcare resource utilization questionnaire
Symptom-directed physical examination
Weight
Vital signs
Perform SJC66/TJC68
Physician’s global assessment
Obtain blood samples for :
Hematology  and Serum Chemistry
Lipid profile (fasting)
Serum CRP

Biomarker blood samples
PPD
PPD
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page55 05July2016  
Carotid artery  ultrasounds, at selected sites only, when available
Urine stored for potential biomarker anal ysis
Urinalysis (including urine pregnancy  test for females of childbearing potential, as defined 
per protocol )
Review and collection of concomitant medications
Record an y serious adverse events and all adverse events related to protocol mandated 
procedures occurring after signing of the consent form.
6.3. Randomization
Subjects will be randomly allocated to treatment according to a pre-specified randomization 
scheme prepared b y an independent statistician Upon qualification for the study, subjects will be 
randomized using a computerized I WRS system. Randomization will be stratified b ygeographic
region, prior exposure to number of bDMARDs ( <3 or >=3 bDMARDs) ,and presence ofRFor 
anti-CCP Abat screening .
For each subject at each visit, the clinic will contact the I WRS system and for the appropriate kit 
number to be dispensed. The kit will contain the relevant study medication for the period until 
the next visit.
6.4. Week 2 through Week 20 Assessments
The following assessments will be completed at each visit or as specified. All assessments are 
summarized in the Study Procedures Table ( Appendix 2).
Subject’s Global Assessment, HAQ -DIand Pain Scale , FACIT-
Fatigue,andSF-36are 
recommended to be completed before an y other study procedures. Invasive study  procedures 
such as blood draws should be done at t he end of a study  visit. 
Subject global assessment
Subject’s pain assessment
HAQ-DIand pain scale
FACIT-Fatigue, SF-36at Weeks 4 and 12 
WPAI-RA, EQ- 5Dat Weeks4 and 12, where available
PPD
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page56 05July2016
TSQM at Week 12 , when and where available
Healthcare resource utilization questionnaire at Week 12 
Symptom-directed phy sical examination
Weight
Vital signs
Physician’s global assessment
Perform SJC66/TJC68
12-Lead ECG at Week 12 
Obtain blood samples for :
Hematology  and Serum chemistry
Lipid profile (fasting) at Week 12 
Serum CRP
Pharmacokinetic (PK: Weeks 4, 12, and 16)
Biomarker blood samples at Weeks 4, 8, and 12
Urine pregnancy  test (for females of childbearing potential , as defined per protocol)
Urine biomarker sample at Week 12
6.5. Week 24/Early Termination
If a subject discontin ues the study dosing (for example, as a result of an AE ),every attempt 
should be made perform the required stud y
-related ET visit and post treatment week 4 visist (see 
Section3.5, Criteria for Discontinuation of Study Treatment ).
Subject’s Global Assessment, HAQ -DIand Pain Scale , FACIT-Fatigue, andSF-36are 
recommended to be completed before an y other study procedures. Invasive study  procedures 
such as blood draws should be done at t he end of a study  visit. 
Subject global assessment
Subject’s pain assessment
PPD
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page57 05July2016HAQ-DIand Pain Scale
FACIT-Fatigue, SF-36 
WPAI-RA, EQ- 5D, where available 

TSQM, when and where available
Healthcare resource utilization questionnaire
Perform SJC66/TJC68
Vital signs
Complete Physical examination
Weight
Physician’s global assessment
12-Lead ECG
Obtain blood samples for :
Hematology  Serum chemistry
Lipid profile (fasting)
Serum CRP
Pregnancy  test (serum required if subject is entering into LTE)
Pharmacokinetic (PK)
Biomarker blood samples
Quantitative Ig
  
Urinalysis(including urine pregnancy  test for females of childbearing potential, as defined 
per protocol )
Urine stored for biomarker anal ysis
Assessment of serious AE(s)/ (S)AE(s) and concomitant medication
PPD
PPD
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page58 05July2016Carotid artery  ultrasounds at Week 24, at selected sites only  and when available
Review Entry  criteria for LTE(if applicable)
6.6. Post-treatment Week 4 Assessments
The following procedures will be completed 4 Weeks after the subject’s last dose of study 
treatment . This visit is not applicable if subject is continuing onto the LTEstudy.
Symptom Directed Physical examination
Vital signs
Weight
12-lead ECG
Urine pregnancy  test( for females of childbearing potential , as defined per protocol)
Urinalysis
Obtain blood samples for :
Hematology  and Serum chemistry
6.7. Study Assessments
6.7.1. Efficacy
Efficacy assessments will be carried out at Day  1 and at Weeks 2, 4, 8, 12,
14,16, 20 and 24, or 
at ET(if applicable). 
Assessments of RA will include the derived ACR (ACR20, 50, 70 as well as ACR -N and 
EULAR r esponse criteria, DAS28 [CRP], CDAI , and SDAI  as well as the individual components 
of the ACR resp onse criteria [TJC68, SJC66, HAQ -DI, Physician’s Global assessment, Subject’s 
Global Assessment, Subject’s Assessment of Arthritis Pain and CRP] .
Additionally  subjects will be asked to complete questionnaires, including the FACIT-F atigue
scale, SF-36, EQ-5D, TSQM, WPAI-RA at Day 1 and at Weeks 4,12, 24,or atET(if 
applicable). Healthcare resource utilization wil l be assessed at the same time points.
6.7.1.1. Evaluation of Disease Activity: Tender and Swollen Joint Counts
Assessment of tender and swollen joints will take place at the time points indicated in the study 
procedures table ( Appendix 2)
.
Each of 68 joints will be evaluated for tenderness and each of 66joints will be evaluated for 
swelling (a list of joints to be evaluated is provided in ( Appendix 7). 
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page59 05July2016An independent joint assessor with adequate training and experience in performing joint 
assessments will be designated at each stud y site to perform all joint assessments , and should be 
blinded to the other study assessments performed on the day . The join t assessor should 
preferably be a rheumatologist; however, if a rheumatologist is not available, it should be a 
health care worker with experience in performing joint assessments. The assessor should remain 
the same throughout the study  per subject, as muc h as possible. I t is required that the designated 
joint assessor identify  an appropriate back up assessor to provide coverage if the designated joint 
assessor is absent.
6.7.1.2. Subject’s Global Assessment of Disease Activity
The Subject’s Global assessment of Dis ease Activity  will be performed at the time points 
indicated in the study  procedures table ( Appendix 2).TheSubject’s Global assessment of 
Disease Activity  should be completed before any  other study  procedures .
The Subject’s Global Assessment of Disease A ctivity will be recorded on a 0-100 mm visual 
analog scale (VAS), with 0 indicating “ no arthritis” and 100 indicating “ severearthritis”.
6.7.1.3. Physician’s Global Assessment of Disease Activity
The Physician’s Global assessment of Disease Activity  will be perfor med at the time points 
indicated in the study  procedures table ( Appendix 2).
The Physician’s Global Assessment of Disease Activity  will be recorded on a 0-100 mm VAS, 
with 0 indicating “no disease activity ” and 100 indicating “ maximum disease activit y”. The 
evaluating ph ysician and the subject 
shouldcomplete the global assessments independently  of 
each other.
6.7.1.4. Serum CRP
The subject’s serum CRP will be measured at the time points indicated in the study  procedures 
table (Appendix 2).
6.7.1.5. Health Assessment Questionnaire – Disability  Index and Pain Scale
The functional status of the subject will be assessed using the HAQ -DI at the time points 
indicated in the study  procedures table ( Appendix 2) and should 
be completed before an y other 
study procedures. The HA Q-DI is a 20-question instrument that assesses the degree of difficulty  
a person has in accomplishing tasks in 8 domains (dressing, arising, eating, walking, h ygiene, 
reaching, gripping and errands/chores). Responses are scored on a 4 -
point Likert scale fr om 0, 
indicating no difficulty , to 3, indicating inability  to perform a task in that area. The n eed for aids
or help from another person will also be recorded. The HAQ -DItotal score ranges from 0 to 
3with higher scores indicating greater d ysfunction.
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page60 05July2016As part of the HAQ -DI, subjects will be asked to assess their average pain during the last week 
on a 0-100 mm VAS, with 0 indicating “no pain” and 100 indicating “severe pain”. This 
assessment should be completed before the joint examination. This pain score will be used to 
drive the ACR20/50/70.
6.7.1.6. FACIT-Fatigue Scale
The FACIT -Fatiguescale (version4) will be completed at the time points indicated in the study  
procedures table ( Appendix 2) and should be completed before an y other study procedures where 
local language questionnaires are available
.The FACIT -Fatigue  measures an individual’s level 
of fatigue during their usual daily activities over the past week. It consists of 13 questions with a 
7-day recall period on a 5- point Likert scale, with 0 indicating “not at all” and 4 indicating “very  
much”. Th
e total score ranges from 0 to 52. Higher scores indica te a better the quality  of life.
6.7.1.7. 36- Item Short-form Health Survey  
The SF-36 (version 2) will be completed at the time points indicated in the study  procedu
res 
table (Appendix 2) and should be completed before an y other study procedures .
The SF-36 is a health related quality  of life instrument consisting of 36
questions belonging to 
8domains in 2 components and covers a 4 -week recall period:
physical well -being: 4domains: phy sical functioning (10 items), role phy sical (4items), 
bodily pain (2items), and general health perceptions (5 items)
mental well -
being: 4domains: vitality  (4items), social functioning (2 items), role emotional 
(3items), and mental h ealth (5items)
The remaining item (health transition) is not part of the above domains but is kept separately . 
These scales will be rescaled from 0 to 100 (converting the lowest possible score to 0 and the 
highest possible score to 100), with higher score s indicating a better quality  of life.The SF-36 
isnot disease specific and has been validated in numerous health states.
6.7.1.8. EuroQol 5 Dimensions 
The EQ-5D questionnaire will be completed at the time points indicated in the study  procedures 
table (Appendix 2) and should be completed done before an y other stud y procedures where local 
language questionnaires are available.
The EQ-5D is a standard measure of health status developed by  the EuroQol Group to provide a 
simple, generic measure of health for clinic al and economical appraisal {The EuroQol Group 
1990}. The EQ-5D is not disease specific and has been validated in numerous health states.
The tool consists of the EQ -5D descriptive sy stem and the EQ VAS. The descriptive part 
comprises 5 dimensions (mobility , self-care, usual activities, pain/discomfort, and 
anxiety/depression). Each of these 5 dimensions has 3 levels (no problem, some problems, and 
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page61 05July2016severe problems). Results for each of the 5 dimensions are combined into a 5 -digit number to 
describe the subject’s health state. The VAS records the subject’s health on a 0-100mm VAS 
scale, with 0 indicating “the worst health you can imagine” and 100 indicating “the best health 
you can imagine”.
6.7.1.9. Work Productivity  and Activity  Impairment for Rheumatoid Arthritis
The WPAI -RA is a questionnaire developed to measure impairmen ts in work activities in 
subjects with RA {
Zhang et al 201 0} and will be completed at the time points indicated in the 
study procedures table ( Appendix 2) and shouldbe done before an y other study procedures ,
where local language questionnaires are available .
The questionnaire consists of 6 questions (currentl y employed, work time missed due to RA, 
Work time missed due to other reasons, hours actually  worked, degree RA affected productivity  
while working [0 -10 VAS; with 0 indicating no effect and 10 indicating RA completel y 
prevented the subject from working], and degree RA affected productivity in regular unpaid 
activities [0 -10 VAS; with 0 indicating no effect and 10 indicating RA completely  prevented the 
subject’s daily  activities]). The recall period for questions 2 to 6 is 7 days.
Four main outcomes (expres sed in percentages) can be obtained from the WPAI -RA: percentage 
of work time missed due to RA, percentage of impairment due to RA, percentage of overall work 
impairment due to RA, percentage of activity
 impairment due to RA. Note that for subjects who 
didnot work during the 7 days covered by  the WPAI -RA, the percent overall work impairment 
will be equal to the percent of work time missed due to RA.
6.7.1.10. Healthcare Resource Utilization
The Healthcare Resource Utilization Questionnaire is designed to assess heal thcare usage during 
the previous three months across a number of direct medical cost domains. 
This questionnaire should be completed b y the patient prior to any  procedures being performed 
at the visit, if possible where local language questionnaires are a vailable.
6.7.1.11. Exploratory  patient reported outcomes
 
 
PPD
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page62 05July20166.7.1.12. Treatment Satisfaction Questionnaire for Medication (TSQM) 
The TSQM will assess the overall level of satisfaction or dissatisfaction with medication subjects
are taking. Subjects will be asked to rate their treatment satisfaction at the time points indicated 
in the study  procedures table ( Appendix 2). The TSQM will implemented when and where local 
language TSQM  are available .
6.7.2. Safety and Tolerability
Adverse events (AEs), phy sical examinations, vital signs, 12-lead electrocardiograms (ECG) and 
laboratory  assessments (standard hematology , serum/plasma chemistry ,  and urinaly sis).
6.7.3. Clinical Laboratory Evaluations
The hematology  and serum chemistry  laboratory  analyses will be performed at a central 
laboratory . Reference ranges will be supplied by  the central laboratory  and will be used by  the 
investigator to assess the laboratory  data for clinical significance and pathological changes.
Blood samples will be collected by  venipuncture (or optional 
indwelling catheter for 
pharmacokinetic samp ling days) in the arm at the time points indicated in the study  procedures 
table (Appendix 2). In addition, urine samples for the clinical laboratory  assessments will be 
collected. Subjects onl y need to be fasted at days were lipid profiling is scheduled. 
Please refer to Appendix 6for table of Clinical laboratory tests.
The laboratory  values outside the normal range will be flagged and clinical relevance will be 
assessed b y the investigator. More frequent sampling as well as additional tests may be 
performed as deemed necessary  by the investigator as indicated.
Note that in thecase where 
clinically significant laboratory test results are a potential reason for 
discontinuation from the study drug and withdrawal from the study , retesting of the affected 
parameter(s) should be prompt (within 3 to 7 days) after the investigator has consulted with the 
medical monitor. A decision regarding subject discontinuation should be made after the results 
from the retest are available (see Section 3.5for additional information).
The details of sample handling and shipment instructions will be provided in a separate 
laboratory  manual.  
6.7.4. Vital Signs
Vital signs will be measured at the time points indicated in the study  procedures table 
(Appendix 2).
Vital signs should be taken after the subject has been resting for 5 min and will include heart 
rate, respiratory  rate, SBP, DBP, and body  temperature.
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page63 05July20166.7.5. Physical Examination
A physical examination shouldbe performed at the time points indicated in the study procedures 
table (Appendix2).
Any changes from Baseline will be recorded. Height should be measured at Screening only .
At Screening, and Week 24 (or at ET), a complete phy sical examination including weight should 
be performed. S ymptom-directed ph ysical examinations should be performed at all other visits .
Weight is measured at all visits.
6.7.6. Other Safety Assessments
6.7.6.1.
12-lead Electrocardiogram
A resting 12 -lead ECG will be performed at the time points indicated in the study  procedures 
table (Appendix 2).
The ECG should be obtained after the subject has been resting in the supine position for 5 min 
and will include heart rate (HR), respiratory  rate (RR), QRS, uncorrected QT, morphology , and 
rhythm analy sis. QT interval corrected for HR according to Fridericia (QTcF) wil l be derived 
during the statistical analy sis. ECGs will be interpreted by  the investigator for clinical
significance and results will be entered into the eCRF.
6.8. Pharmacokinetics Assessments
For all subjects, b
lood samples for PK anal ysis should be be collected at least 30 minutes post 
study drug dosing at Week 4, prior to study  drug adm inistration at Week 12 and Week 24, and 
anytime at Week 16 or ET . 
 
 
Plasma concentrations of filgotinib and its metabolite GS-829845 will be analy zed.Additional 
analyses (ie, for MTX and its metabolites) maybe performed.
6.9. Biomarker Assessments
Blood and urine samples will be collected at Day1, Weeks 4, 8, 12, and week 24 or ETfor 
assessment of markers including but not limited to inflammation, immune status, joint damage
and the JAK -STAT pathway .  
Specific informa tion 
regarding the collection and processing of biomarker (if applicable) will be provided to each site 
in a separate laboratory  manual.
PPD
PPD
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page64 05July20167. ADVERSE EVENTS AND TOXICITY  MANAGEMENT
7.1. Definition sof Adverse Events , Adverse Reactions, and Serious Adverse 
Events
7.1.1. Adverse Events
An adverse event (AE) is any  untoward medical occurrence in a clinical study  subject 
administered a medicinal product, which does not necessarily  have a causal relationship with the 
treatment. An AE can therefore be an y unfavorable and/or unintended sign, sy mptom, or disease 
temporally  associated with the use of a medicinal product, whether or not considered re lated to 
the medicinal product. AEs may also include pre -or post-treatment complications that occur as a 
result of protocol specified procedures, lack of efficacy , overdose ,drug abuse/misuse reports , or 
occupational exposure .Preexisting events that increase in severit y or change in nature during or 
as a consequence of participation in the clinical study  will also be considered AEs.
An AEdoes not include the following:
Medical or surgical procedures such assurgery, endoscopy ,tooth extraction, and transfusion. 
The condition that ledto the procedure may  be an adverse event and must be reported.
Pre-existing diseases, conditions, or laboratory  abnormalities present or detected beforethe 
screening visit that donot worsen
Situations where an untoward medical occurrence has not occurred ( ie,hospitalization for 
elective surgery , socialand/or convenience admissions)
Overdose without clinical sequelae (see Section 7.7.1)
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and not related to a protocol -associated procedure is not an 
AE. It is considered to be pre -existing and should be documented on the medical history  
CRF.
7.1.2. Serious Adverse Events
A serious adverse event (SAE) is defined as an event that, at any dose, results in the following:
Death
Life-threatening (Note: The term “life -threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death if it were more severe.)
In-patient hospitalization or prolongation of existing hospitalization
Persistent or significant disability /incapacit y
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page65 05July2016A congenital anomal y/birth defect
A medically important eventor reaction: such events may  not be immediately  
life-threatening or result in death or hospitalization but may  jeopardize the subjector may 
require intervention to prevent one of the other outcomes constituting SAEs. Medical and 
scientific judgment mustbe exercised to determine whether such an event is a reportable 
under expedited reporting rules. Examples of m edically important e vents include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospitalization; anddevelopment of drug dependency  or 
drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal 
product will be considered a m edically important 
event and subject to expedited reporting 
requirements.
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities without clinical significance are not recorded as AEs or SAEs. 
However, laboratory  abnormalities (eg, clinical chemistry , hematology , and urinaly sis) that 
require medical or surgical intervention or lead to study drug interruption, modification, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. I n addition, 
laboratory  or other abnormal assessments (eg, electrocardiogram, x- rays, vital signs) that are 
associated with signs and/or symptoms must be recorded as an AE or SAE if they  meet the 
definition of an AE or SAE as described in Sections 7.1.1and 7.1.2.If the laboratory  
abnormality is part of a sy ndrome, record the s yndrome or diagnosis (eg, anemia), not the 
laboratory  result (ie, decreased hemoglobin).
For specific information on handling of clinical laboratory  abnormalities in this study , please 
refer to Section 7.5.
7.2. Assessment of Adverse Events and Serious Adverse Events
The i
nvestigator or qualified subinvestigator is responsible for assessing AEs and SAEs for 
causality and severity , and for final review and confirmation of accuracy  of event information 
and assessments
.
7.2.1. Assessment of Causality for Study Drugs and Procedu res
The investigator or qualified subinvestigator is responsible for assessing t he relationship to study  
drugtherapy using clinical judgment and the following considerations:
No: Evidence exists that the adverse event has an etiology other than the study drug. For 
SAEs, an alternative causality  must be provided (eg, pre -existing condition, underly ing 
disease, intercurrent illness, or concomitant medication).
Yes:There is reasonable possibility  that the event may  have been caused by the 
investigational med icinal product.
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page66 05July2016It should be emphasized that ineffective treatment should not be considered as causall y related in 
the context of adverse event reporting. 
The relationship to study  procedures (eg, invasive procedures such as venipuncture or biops y) 
shouldbe assessed using the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the study  procedure.
Yes:The adverse event occurred as a result of protocol procedures, (eg.,venipuncture)
7.2.2. Assessment of Severity
The severity of AEs will be graded using the modified CTCAE, version 4.03. For each episode, 
the highest grade attained should be reported.
If a CTCAE criterion does not exist, the investigator should use the grade or adjectives: 
Grade1(mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life -threatening) or 
Grade5(fatal) to describe the maximum intensity  of the adverse event. For purposes of 
consistency  with the CTCAE, these intensity  grades are defined in Table 7-1and Appendix 4.
Table7-1. Grading of Adverse Event Severity
Grade Adjective Description
Grade 1 Mild Asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated 
Grade 2 Moderate Local or noninvasive intervention indicated; limiting age -appropriate 
instrumental ADL 
Grade 3 Severe Severe or medically significant but not immediately life -threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; 
limiting self-care ADL 
Grade 4 Life-threatening Urgent intervention indicated 
Grade 5 Death Death related AE 
*   Activities of Daily Living (ADL) Instrumental ADL refer to opening preparing meals, shopping for groceries or clothes, us ing 
the telephone, managing money, etc. 
**  Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toile t, taking medications, and not bedridden.
7.3. Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to Gilead
Requirements for collection prior to study  drug initiation:
After informed consent, but prior to initiati on of study medication, the following t ypes of events 
should be reported on the case report form (CRF/eCRF): all SAEs and adverse events related to 
protocol-mandated procedures.
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page67 05July2016Adverse Events
Following initiation of study  medication, collect a ll AEs, rega rdless of cause or relationship, 
until 30-daysafter last administration of study  drugmust be reported to the CRF/eCRF database 
as instructed.
All AEs should be followed up until resolution or until the adverse event is stable, if possible. 
Gilead Science s may request that certain AEs be followed bey ond the protocol defined follow up 
period.
Serious Adverse Events
All SAEs, regardless of cause or relationship, that occur safter the subject first consents to 
participate in the stud y (ie, signing the informe d consent) and throughout the duration of the 
study, including the protocol -required post treatment follow -up period, must be reported to the 
CRF/eCRF database and Gilead Drug Safet y and Public Health (DSPH) as instructed. This also 
includes an y SAEs resul ting from protocol -associated procedures performed after informed 
consent is signed.
Any SAEs and deaths that occur after the post treatment follow -up visit but within 30- daysof the 
last dose of study drug, regardless of causalit y, should also be reported. Investigators are not 
obligated to actively  seek SAEs after the protocol defined follow up periodhowever, if the 
investigator learns of an y SAEs that occur after study  participation has concluded and the event 
is deemed relevant to the use of study drug, he/she should promptly  document and report the 
event to Gilead DSPH.
All AEs and SAEs will be recorded in the CRF/eCRF database within the timelines outlined 
in the CRF/eCRF completion guideline.
Electronic Serious Adverse Event (eSAE) Reporting Process
Site personnel record all SAE data in the eCRF database and from there transmit the SAE 
information to Gilead DSPH within 24 hours of the investigator’s knowledge of the event. 
Detailed instructions can be found in the eCRF completion guidelines.
If for any reason it is not possible to record the SAE information electronically , ie, the eCRF 
database is not functioning, record the SAE on the paper serious adverse event reporting 
form and submit within 24 hours as described above.
Gilead DSPH: Fax: 1-650-522-5477
E-mail: Safety _FC@gilead.com
As soon as it is possible to do so, any SAE reported via paper must be transcribed into the 
eCRF Database according to instructions in the eCRF completion guidelines.
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page68 05July2016If an SAE has been reported via a paper form b ecause the eCRF database has been locked, no 
further action is necessary.
All AEs and SAEs will be recorded in the eCRF database within the timelines outlined in the
eCRF completion guideline
For fatal or life -threatening events, copies of hospital case r eports, autops y reports, and other 
documents are alsoto be submitted by e-mail or fax when requested and applicable. 
Transmission of such documents should occur without personal subject identification, 
maintaining the traceability of a document to the subject i dentifiers.
Additional information may  be requested t o ensure the timely  completion of accurate safet y 
reports.
Any medications necessary  for treatment of the SAE must be recorded onto the concomitant 
medication section of the subject’s CRF/eCRF and the event description section of the SAE 
form.
7.4. Gilead Reporting Requirements
Depending on relevant local legislation or regulations, including the applicable US FDA Code of 
Federal Regulations, the EU Clinical Trials Directive (2001/20/EC) and relevant upd ates, and 
other country -specific legislation or regulations, Gilead may  berequired to expedite to 
worldwide regulatory  agencies reports of SAEs, serious adverse drug reactions (SADRs) ,or 
suspected 
unexpected serious adverse reactions (SUSARs). In accordance with the EU Clinical 
Trials Directive (2001/20/EC), Gilead or a specified designee will notify  worldwide regulatory  
agenciesand the relevant IECin concerned Member States of applicable SUSARs as outlined in 
current regulations.
Assessment of e xpectedness forSAEs will be determined by  Gilead using reference safety  
information specified in the i nvestigator’s brochure or relevant local label as applicable. 
All investigators will receive a safet y letter notifying them of relevant SUSAR reports associated 
with any studydrug. The investigator should notify  the IRB or IEC of SUSAR reports as soon as 
is practical, where this is required b y local regulatory agencies, and in accordance with the local 
institutional policy . 
7.5. Clinical Laboratory Abnorm alities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities are usuall y not recorded as AEs or SAEs. However, laboratory  
abnormalities (eg, clinical chemistry , hematology , and urinal ysis) independent of the 
underlyingmedical condition that require medical or surgical intervention or lead to 
investigational medicinal product interruption or discontinuation must be recorded as an AE, as 
well as an SAE, if applicable. In addition, laboratory  or other abnormal assessments 
(eg,electrocardiogram, X -rays, vital signs) that are associated with signs and/or sy mptoms must 
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page69 05July2016be recorded as an AE or SAE if they  meet the definition of an AE (or SAE) as described in 
Sections7.1.1and 7.1.2.  If the laboratory  abnormality  ispart of a s yndrome, record the 
syndrome or diagnosis (ie, anemia) not the laboratory  result (ie, decreased hemoglobin).
Adverse events will be coded using the most recent version of the Medical Dictionary  for 
Regulatory  Activities (MedDRA). Severity  should be recorded and graded according to the 
Common Terminology  Criteria for Adverse Events (CTCAE) Version 4.03, which can be 
foundat:
http://www.hrc.govt.nz/sites/default/files/CTCAE%20manual%20 -%20DMCC.pdf
For AEsassociated with laboratory  abnormalities, the event should be graded on the basis of the 
clinical severit y in the context of the underlying conditions; this ma y or may not be in agreement 
with the grading of the laboratory  abnormality .
All clinical and clinicall y significant laboratory toxicities will be managed according to uniform 
guidelines detailed in Appendix 3, and as outlined below.
7.5.1. Grades 1 and 2 Laboratory Abnormality or Clinical Event
Continue study drugat the discretion of the i nvestigator.
7.5.2. Grades 3 Laboratory Abnormality or Clinical Event
For Grade 3 clinically  significant laboratory  abnormality  or clinical event, investigational 
medicinal product may  be continued if the event is considered to be unrelated to 
investigational medicinal produc t.
For a Grade 3 clinical event, or clinicall y significant laboratory abnormality confirmed b y 
repeat testing, that is considered to be related to investigational medicinal product, 
investigational medicinal product should be withheld until the toxicity  returns to ≤Grade2.
If a laboratory  abnormality  recurs to 
≥Grade3 following re -challenge with investigational 
medicinal product and is considered related to investigational medicinal product, then 
investigational medicinal product should be permanently  discontinued and the subject managed 
according to local practice. Recurrence of laboratory  abnormalities considered unrelated to 
investigational medicinal product may not require permanent discontinuation.
7.5.3. Grades 4 Laboratory Abnorm ality or Clinical Event
For a Grade 4 clinical event or clinicall y significant Grade 4 laboratory abnormality 
confirmed b y repeat testing that is considered related to investigational medicinal product, 
investigational medicinal product should be permanently  discontinued and the subject 
managed according to local practice. The subject should be followed as clinically  indicated 
until the laboratory  abnormality  returns to Baselineor is otherwise explained, whichever 
occurs first. A clinically  significant Grade 4 laboratory  abnormali ty that is not confirmed b y 
repeat testing should be managed according to the algorithm for the new toxicity  grade.
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page70 05July2016Investigational medicinal product may  be continued without dose interruption for a clinically  
non-significant Grade 4 laboratory  abnormality (eg, Grade 4 CK after strenuous exercise or 
triglyceride elevation that is nonfasting or that can be medicall y managed) or a clinical event 
considered unrelated to investigational medicinal product
7.6. Toxicity Management 
Treatment -emergent toxicities will b e noted by  the investigator and brought to the attention of 
the Gilead Sciences medical monitor, who will have a discussion with the investigator and 
decide the appropriate course of action. Whether or not considered treatment -related, all subjects 
experiencing AEs must be monitored periodically  until symptoms subside, any  abnormal 
laboratory  values have resolved or returned to Day 1
levels or they  are considered irreversible, or 
until there is a satisfactory explanation for the changes observed. Grade 3 or 4 clinically  
significant laboratory  abnormalities should be managed as outlined in Appendix 3and 
Section7.5.2and 7.5.3.
Any questions regarding toxicity  management should be directed to the Gilead Sciences 
MedicalMonitor.
7.7. Special Situations Reports
7.7.1. Definitions of Special Situations
Special situation reports includ e all reports of medication error, abuse, misuse, overdose, reports 
of adverse events associated with product complaints, occupational exposure with an AE, 
pregnancy  reports regardl ess of an associated AE and AE in an infant following exposure from 
breastfeeding .  
Medication error is any unintentional error in the prescribing, dispensing ,or administration of a 
medicinal product while in the control of the health care provider , subject,or consumer.
Abuse is defined as persistent or sporadic intentional excessive use of a medicinal product by  a 
subject.
Misuse 
is defined as an y intentional and inappropriate useof a medicinal p roduct tha t is not in 
accordance with the protocol instructions or the local prescribing information .
An overdose is defined as an accidental or intentional administration of a quantity  of a medicinal 
product given per administration or cumulatively  which is above the maximum recommended 
dose as per protoc ol or in the product labelling (as it applies to the daily  dose of the subject in 
question). In cases of a discrepancy  in drug accountability , overdose will be established only  
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot account for the discrepancy  except in cases in which the investigator has 
reason to suspect that the subject has taken the additional dose(s).
Product complaint is defined as complaints arising from potential deviati ons in the manufacture, 
packaging, or distribution of the medicinal product.
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page71 05July2016Occupational exposure is defined as exposure to a medicinal product as a result of one's 
professional or non- professional occupation. 
7.7.2. Instructions for Reporting Special Situatio ns
7.7.2.1. Instructions for Reporting Pregnancies
The investigator should report pregnancies in female study  subjects that are identified after 
initiation of study  medication and throughout the study , including the post study  drug follow -up 
period, to Gilead DSPH using the pregnancy  report form within 24 hours of becoming aware of 
the pregnancy . 
Refer to S ection7.3and the CRF/eCRF completion guidelines for full instructions on the 
mechanism of pregnancy reporting.
The pregnancy  itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy  without medical reasons.
Any premature termination of pregnancy  (eg, a spontaneous abortion, an induced thera peutic 
abortion due to complications or other medical reasons) must be reported within 24 hours as an 
SAE. The underl ying medical reason for this procedure should be recorded as the AEterm.
A spontaneous abortion is alway s considered to be an SAE and w illbe reported as described in 
Sections7.1.1and 7.1.2. Furthermore, an y SAE occurring as an adverse pregnancy  outcome post 
study must be reported to Gilead DSPH
The subject should receive appropriate monitoring and care until the conclusion of the 
pregnancy. The outcome should be reported to Gilead DSPHusing the pregnancy  outcome report 
form. If the end of the pregnancy  occurs after the study  has been completed, the outcome should 
be reported directl y to Gilead DSPH. Gilead DSPH contact information is as f ollows:
Email: Safety _FC@gilead.com and Fax: +1 (650) 522 -
5477.
Pregnancies of female partners of male stud y subjects exposed to study  drugs must also be 
reported and relevant information should be submitted to Gilead DSPH using the pregnancy  and 
pregnancy outcome forms within 24 hours. Monitoring of the subject should continue until the 
conclusion of the pregnancy . If the end of the pregnancy occurs after the study  has been 
completed, the outcome should be reported directly  to Gilead DSPH,
fax number +1 65 0 522-5477 or email Safety_FC@gilead.com. 
Refer to Appendix 5for Pregnancy  Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive Requirements
.
7.7.2.2. Reporting Other Special Situations
All other special situation reports must be report ed on the special situations report form and 
forwarded to Gilead DSPH within 24 hours of the investigator becoming aware of the situation. 
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page72 05July2016These reports must consist of situations that involve study  drugand/or Gilead concomitant 
medications, but do not apply to non-Gilead concomitant medications. 
Special situations involving non-Gilead 
concomitant medications doesnot need to be reported on 
the special situions report form; however, for special situations that result in AEs due to a non -
Gilead concomitant medication, the AE should be reported on the AE form . 
Any inappropriate use of concomitant medications prohibited by  this protocol should not be 
reported as “misuse,” but may  be more appropriately  documented as a protocol deviation.
Refer to Section 7.3and the CRF/eCRF completion guidelines for full instructions on the 
mechanism of special situations reporting.
All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs 
at the same time using the AE CRF/eCRF and/or the SAE report form. Details of the sy mptoms 
and signs, clinical management, and outcome will be reported, when available.
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page73 05July20168. STATISTICAL  CONSIDER ATIONS
8.1. Analysis Objectives and Endpoints
8.1.1. Analysis Objectives
The primary  objective of this study is:
To evaluate the effects of filgotinib versus placebo for the treatment of signs and sy mptoms 
of rheumatoid arthritis (RA)as measured b y the proportion of subjects achieving an 
American College of Rheumatology  20% improvement response (ACR20) at Week12 
The secondary  objectives of this study  are: 
To evaluate the effects of filgotinib versus placebo for the treatment of signs and sy mptoms 
of RA as measured by the proportion of subjects achieving Disease Activity Score for 28 
joint count using c-reactive protein (DAS28 [CRP]) ≤3.2 at Week 12
To evaluate the effect of filgotinib versus placebo on phy sical function as measured by  
change from Baseline in the Health Assessment Questionaire Disability  Index (HAQ -DI) at 
Week 12
To evaluate the safet y and tolerability of filgotinib
To evaluate the effects of filgotinib on work productivity , fatigue, and general quality  of life 
as measured b y SF-36, FACI T-Fatigue, EQ-5 and WPAI -RA.
The exploratory  objective of this study  is as follows: 
 
 
 
8.1.2. Primary Endpoint
The primary  endpoint is the proportion of subjects who achievean ACR20 response at Week 12.
PPD
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page74 05July20168.1.3. Secondary Endpoint s
The key secondary  endpoints are:
The proportion of subjects who achieve DAS28 (CRP)≤3.2 
at Week 12
Change from Baselinein the HAQ- DI score at Week 12
Other secondary  endpoints include:
The proportion of subjects who achieve ACR50 and ACR70 at Weeks 4, 12 and 24, ACR20 
at Weeks 4 and 24, and ACR20/50/70 over time from Day 1through Week 24
Change from Baselinein individual components of the ACR response at Weeks 4,12, and 24 
and over time from Day  1through Week 24 
The proportion of subjects who achieve change in HAQ -DI of ≥0.22 at Weeks 4, 12, and 24, 
and over time from Day 1through Week 24
Change from Baselinein DAS28 (CRP) at Weeks 4, 12, 24 and over time from Day 1
through Week 24
The proportion of subjects who achieve DAS28(CRP)≤3.2 at Weeks 4 and 24, and over time 
from Day 1through Week 24
The proportion of subjects who achieve DAS28(CRP)<2.6 at Weeks 4, 12, and 24, and over 
time from Day 1through Week 24
ACR-N and EULAR  response at Weeks 4, 12, and 24, and over time from Day 1through 
Week 24 
Change from Baselinein CDAI at Weeks 4, 12, and 24, and over time from Day 1through 
Week 24 
Change from Baselinein SDAI at Weeks 4, 12, and 24, and over time from Day 1through 
Week 24 Absolute value and change from Baselinein SF-
36, FACIT -Fatigue,and the 
EQ-5D over time at Weeks 4, 12 and 24, and over time from Day 1through Week 24
Absolute 
value and change from Baselinein WPAI-RAat Weeks 4, 12, 24, and over time 
from Day 1through W eek 24 
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page75 05July20168.2. Analysis Conventions
8.2.1. Analysis Sets
8.2.1.1. All Randomized
The all randomized analysis set includes all subjects who are randomized in the study. This is the 
primary analysis set for by -subject listings.
8.2.1.2. Efficacy
8.2.1.2.1. Full Anal ysis Set (FAS)
The primary  analysis set for efficacy  analyses will be the Full Anal ysis Set (FAS), which 
includes all randomized subjects who received at least one dose of study  drug.
8.2.1.2.2. Per- Protocol (PP) Anal ysis Set
The secondary  analysis set for efficacy  analyses will be the Per -Protocol (PP) Analy sis set, 
which includes all subjects in the Full Analy sis Set who ha ve not committed any  major protocol 
violation, including the violation of key  entry criteria. 
8.2.1.3. Safety
The primary  analysis set for safety
 analyses will be the Safet y Analysis Set ,which includes all 
subjects who received at least one dose of stud y drug.
8.2.1.4. P harmacokinetic 
8.2.1.4.1. Pharmacokinetic (PK) Substudy  Analysis Set
 
 
8.2.1.4.2. Pharmacokinetic (PK) Analy sis Set
The primary  analysis set for general PK analy ses will be the PK anal ysis set, which includes all 
subjects in the Safety Analysis Set who have at least 1 nonmissing concentration data for 
filgotinib and/or its metabolite GS-829845 .
8.3. Data Handling Conventions
PK concentration values and PK parameter values below the limit of quantitation (BLQ) wil l be
presented as “BLQ” in the data listings. BLQ values that occur prior to the first dose will be
treated as 0, BLQ values at all other time points will be treated as 1/2 of the lower limit of
quantitation (LLOQ).
PPD
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page76 05July2016Laboratory  data that are continuous in nature but are less than the lower limit of quantitation or
above the upper limit of quantitation will be imputed to the value of the lower or upper limit
minus or plus one significant digit, respectivel y (eg, if the result of a continuous laboratory  test is
< 20, a value of 19 will be assigned; if the result of a continuous laboratory test is < 20.0, a value 
of 19.9 will be assigned).
8.4. Demographic Data and Baseline Characteristics
Demographic and Baseline characteristics will be summarized by treatment grou pusing standard 
descriptive statistics including sample size, mean, SD, median, Q1, Q3, minimum, and maximum 
for continuous variables and numbersand percentages of subjects for categorical variables.
Demographic data will include sex, race, ethnicity , and age.
Baselinecharacteristics may  include number of prior bDMARD exposure, RFstatus, anti- CCP 
status, DAS28(CRP), HAQ- DI, SDAI, CDAI ,and other variables of interest.
8.5. Efficacy Analysis
8.5.1. Primary Analysis
The primary  endpoint for the study  is the proportion of subjects who achieve an ACR20 response 
at Week12. The primary anal yses will consist of a superiorit y test of filgotinib 200 mg 
compared to placebo based on the ACR20 response rate at Week 12 . Cochran
-Mantel-Haenszel
(CMH)approach adjusting for the randomization stratification factor s will be used for the 
hypothesistesting at the 2 -sided 0.05- level. 
Subjects who do not have sufficient measurements to 
establishefficacy at week 12 will be considered failures (i.e. non -responder imputation [NRI ]).  
Sensitivity  analyses will be described in the statistical anal ysis plan (SAP).
8.5.2.
Secondary Analyses
The following h ypothesis testing will commence after the primary  analysis reaches statistical 
significance, and will be tested according to the hierarchical testin g principle at the 2 -sided 
0.05level.If a null h ypothesis is not rejected, formal sequential testing will be stopped and only  
nominal significance will be reported for the remaining hypotheses:
1) Superiority  of filgotinib 200 mg compared to placebo based on the response rate of DAS28 
(CRP)≤3.2 at Week 12 . 
2)Superiority  of filgotinib 200 mg compared to placebo based on the change from Baselinein 
HAQ-DI at Week 12. 
3)Superiority  of filgotinib 100 mg compared to placebo based on ACR20response rate at 
Week 12
. 
4)Superiority  of filgotinib 100 mg compared to placebo based on the response rate of DAS28 
(CRP)≤3.2 at Week 12 . 
5)Superiority  of filgotinib 100 mg compared to placebo based on the change from Baseli nein 
HAQ-DI at Week 12. 
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page77 05July2016For categorical endpoints (ACR20 and response rate of DAS28 (CRP) ≤3.2), the same CMH
approach with NRI as used for the primary  analysis will be adopt ed.For continuous endpoint 
(HAQ-DI), mixed-
effects model for repeated measures (MMRM) will be used to evaluate 
treatment effect on change from baseline . Treatment, visit, treatment -by-visit interaction, 
stratification factors and baseline value maybe included in the modelas fixed effects, wi th 
subject being a radom effect .
For other secondary  endpoints listed under Section 8.1.3summary statistics will be provided by  
treatment group. Differences across treatment groups will be summarized and treatment 
comparisons may  be performed. Details on efficacy analyses will be described in the SAP.
8.6. Safety Analysis
All safety analyses will be performed using the safety  analysis set.
Safety will be evaluated by  assessment of clinical laboratory  tests, phy sical examinations, vital 
signs measurements at various time points during the study , and by the documentation of AEs.
All safety data collected on or after the first dose of study drug administration up to 30 days after 
the last dose of study  drug, unless specified otherwise ,will be summarized by  treatment group 
according to the stud y drug received.
8.6.1. Extent of Exposure
A subject’s extent of exposure to study  drug will be generated from the study  drug 
administration page of the eCRF. Exposure data will be summarized by  treatment group.
Duration of exposu re to study  drug will be expressed as the number of weeks between the first 
and last dose of the stud y drug, inclusive, regardless of temporary interruptions in study  drug 
administration and summarized by  treatment group .
8.6.2. Adverse Events
Clinical and labor atory adverse events will be coded using the Medical Dictionary  for 
Regulatory  Activities (MedDRA). Sy stem Organ Class (SOC), High -Level Group Term 
(HLGT), High-Level Term (HL T), Preferred Term (PT), and Lower -Level Term (LLT) will be 
attached to the clin ical database.
Treatment -Emergent Adverse Events (TEAEs) are:
Any AEs with an onset date of on or after the study  drug start date and no later than 30 day s
after permanent discontinuation of study  drug or
Any AEs leading to premature discontinuation of stu dy drug.
Summaries (number and percentage of subjects) of TEAEs by  SOCand PT will be provided by  
treatment group . TEAEs will also be summarized by  relationshiop to study
 drug and severity . In 
addition, TEAEs leading to premature discontinuation of study  drug will be summarized and 
listed.
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page78 05July20168.6.3. Laboratory Evaluations
Selected laboratory  data will be summarized (n, mean, SD, median, Q1, Q3, minimum, and
maximum) by  treatment group and study  visit along with corresponding change from Baseline. 
The incidence of treatment- emergent graded laboratory  abnormalities will be summarized 
similarly.
Graded laboratory  abnormalities will be defined using CTCAE 4.03 grading scale.
8.7. Pharmacokinetic Analysis
Plasma concentrations of filgotinib and itsmetabolite ( GS-829845) will be listed and 
summarized for all subjects by treatment using descriptive statistics ( eg,sample size, arithmetic 
mean, geometric mean, % coefficient of variation, standard deviation, median, minimum , and 
maximum ).
 
 
 
 
Exposure -response anal ysis may be performed.
8.8. Biomarker Analysis
 
 
 
 
8.9. Sample Size
Sample size is determined based on the superiority test of filgotinib compared to placebo on the 
change from Baselinein HAQ-DI at Week 12. When assuming 
a difference of 0.25 between the 
two groups and a common standard deviation of 0.645, 141 subjects in each of the filgotinib 
groupsand placebo control group are required to obtain 90% power at a 2 -sided 0.05 -level. 
A sample size of 141 subjects in each o f the filgotinib group s and placebo control group will 
also provide over 90% power to detect an increase in A CR20 response rate of 25% to 45% 
between the placebo control group and the filgotinib group srespectively, using a 2 -sided 
0.05-level test.
PPD
PPD
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page79 05July2016In summary, the total sample size will be 423 (141 per group).
8.10. Data Monitoring Committee
An external multidisciplinary  data monitoring committee (DMC) will review the progress of the 
study and perform interim reviews of safet y data and provide recommendation to Gilead whether 
the nature, frequency , and severit y of adverse effects associated with stud y treatment warrant the 
early termination of the study in the best interests of the participants, whether the stud y should 
continue as planned, or the study  should continue with modifications. 
The initial reviews will be conducted after approximately 100 subjec ts enrolled complete through 
12weeks of treatment . The DMC’s specific activities will be defined by  a mutually  agreed 
charter, which will define the DMC’s membership, conduct and meeting schedule.
While the DMC will be asked to advise Gilead regarding future conduct of the study , including 
possible earl y study termination, Gilead retains final decision -making authority  on all aspects of 
the study.
8.11. Cardiovasc ular Endpoint Adjudication Committee
A Cardiovascular Endpoint Adjudication Committee (CV -SEAC) consisting of at least 
2cardiologists and governed by  a Charter will be set up to perform adjudication of Major 
Adverse Cardiovascular Events occurring during the study. The adjudication of these events will 
be performed in a blind edfashionfor the purposes of data analy sis, and not for monitoring of 
subject safet y. 
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page80 05July20169. RESPONSIBILITIES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The investigator will ensure that this study  is conducted in accordance with the principles of the 
Declaration of Helsinki (as amended in Edinburgh, Toky o, Venice, Hong Kong, and 
SouthAfrica), International Conference on Harmonisation (I CH) guidelines, or with the laws and 
regulations of the country in which the research is conducted, whichever affords the greater 
protection to the study  subject.These standards are consistent with the European Union Clinical 
Trials Directive 2001/20/EC and Good Clinical Practice Directive 2005/28/EC.
The investigator will ensure adherence to the basic principles of Good Clinical Practice, as 
outlined in 21 CFR312, subpart D, “Responsibilities of Sponsors and Investigators,” 21 CFR, 
part50, 1998, and 21 CFR, part 56, 1998.
The investigator and all applicable subinvestigators will comply  with 21CFR, Part 54, 1998, 
providing documentation of their financial interest or arrangements with Gilead, or proprietary  
interests in the investigational drug under stud y. This documenta tion must be provided prior to 
the investigator’s (and any  subinvestigator’s) participation in the study . The investigator and 
subinvestigator agree to notify  Gilead of an y change in reportable interests during the stud y and 
for 1 year following completion of the study . Study completion is defined as the date when the 
last subject completes the protocol- defined activities.
9.1.2. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Review and Approval
The investigator (or sponsor as appropriate according to local regulations) will submit this 
protocol, informed consent form, and an y accompanying material to be provided to the subject 
(such as advertisements, subject information sheets, or descriptions o f the study  used to obtain 
informed consent) to an IRB/IEC. The investigator will not begin an y study subject activities 
until approval from the IRB/IEC 
has been documented and provided as a letter to the 
investigator.
Before implementation, the investigat or will submit to and receive documented approval from 
the IRB/IECany modifications made to the protocol or any accompan ying material to be 
provided to the subject after initial I RB/IEC approval, with the exception of those necessary  to 
reduce immediate r isk to study  subjects.
9.1.3. Informed Consent
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study  and before undertaking an y study-related procedures. The 
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page81 05July2016investigator must use the most current IRB/IEC-approved consent form for documenting written 
informed consent. Each informed consent (or assent as applicable) will be appropriatel y signed 
and dated b y the subject and the person conducting the consent discussion, and also b y an 
impartial witness if required b y IRB/IEC or local requirements. The consent form will inform 
subjects about genomic testing and sample retention, and their right to receive clin ically relevant 
genomic anal ysis results.
9.1.4. Confidentiality
The investigator must assure that subjects’ anon ymity will be strictly  maintained and that their 
identities are protected from unauthorized parties. Only subject initials, date of birth, another 
unique identifier (as allowed b y local law) and an identification code  will be recorded on an y 
form or biological sample submitted to the Sponsor, IRB/IEC,or laboratory . Laboratory  
specimens must be labeled in such as way  as to protect subject identity while allowing the results 
to be recorded to the proper subject. Refer to specific laboratory  instructions. NOTE: The 
investigator must keep a screening log showing codes, names, and addresses for all subjects 
screened and for all subjects enrolled in the trial. Subject data will be processed in accordance 
with all applicable regulations. 
The investigator agrees that all information received from Gilead, including but not limited to the 
investigator brochure, this protocol, CRF/eCRF, the study drug, and any other study information, 
remain the sole and exclusive propert y of Gilead during the conduct of the study and thereafter. 
This information is not to be disclosed to an y third party (except emplo yees or agents directly  
involved in the conduct of the study  or as required by  law) without prior written consent from 
Gilead. The investigator further agrees to take all reasonable precautions to prevent the 
disclosure b y any employee or agent of the stud y site to any  third party  or otherwise into the 
public domain.
9.1.5. Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the stud y 
to be fully  documented and the study data to be subsequently  verified. These documents should 
be classified into at least the following two categories: (1)investigator’s study  file, and 
(2)subject clinical source documents.
The investigator’s stud y file will contain the protocol/amendments, CRF and query  forms, 
IRB/IEC and governmental approval with correspondence, informed co nsent, drug records, staff 
curriculum vitae and authorization forms, and other appropriate documents and correspondence.
The required source data should include sequential notes containing at least the following 
information for each subject:
Subject identi fication (name, date of birth, gender);
Documentation that subject meets eligibility  criteria, ie, history , physical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria);
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page82 05July2016Documentation of the reason(s) a consented subjec t is not enrolled
Participation in study  (including study  number);
Study discussed and date of informed consent;
Dates of all visits;
Documentation that protocol specific procedures were performed;
Results of efficacy  parameters, as required b y the protocol;
Start and end date (including dose regimen) of study drug, including dates of dispensing and 
return;
Record of all adverse events and other safety parameters (start and end date, and including 
causality and severity );
Concomitant medication (including s tart and end date, dose if relevant; dose changes);
Date of stud y completion and reason for earl y discontinuation, if it occurs.
All clinical study  documents must be retained b y the investigator until at least 2 years or 
according to local laws, whichever is longer, after the last approval of a marketing application in 
an ICH region (ie, United States, Europe, or Japan) and until there are no pending or planned 
marketing applications in an I CH region; or, if no application is filed or if the application is not 
approved for such indication, until 2 years after the investigation is discontinued and regulatory 
authorities have been notified. Investigators may  be required to retain documents longer if 
specified b y regulatory  requirements, by  local regulations, or by  an agreement with Gilead. The 
investigator must notify  Gilead before destro ying any clinical study  records.
Should the investigator wish to assign the stud y records to another part y or move them to another 
location, Gilead must be notified in advance.
If the investigator cannot provide for this archiving requirement at the study site for an y or all of 
the documents, special arrangements must be made between the investigator and Gilead to store 
these records securel y away from the site so that they can be returned sealed to the investigator 
in case of an inspection. When source documents are required for the continued care of the 
subject, appropriate copies should be made for storage away  from the site.
9.1.6. Case Report Forms
For each subject consented, an eCRF will be completed by  an authorized study  staff member 
whose training for this function is documented according to study  procedures. eCRF should be 
completed on the day  of the subject visit to enable the sponsor to perform central monitoring of 
safety data.  The Eligibility  Criteria eCRF should be completed onl y after all data related to 
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page83 05July2016eligibility  have been received.  Subsequent to data entry , a study monitor will perform source 
data verification within the EDC system. Original entries as well as any  changes to data fields 
will be stored in the audit trail of the sy stem.  Prior to database lock (or any  interim time points 
as described in the clinical data management plan), the investigator will use his/her log in 
credentials to confirm that the forms have been reviewed, and that the entries accuratel y reflect 
the information in the source documents. The eCRF capture the data required per the protocol 
schedule of events and procedures. System-generated or manual queries will be issued to the 
investigative site staff as data discrepancies are identified by  the monitor or internal Gilead staff, 
who routinely  review the data for completeness, correctness, and consistency . The site 
coordinator is responsible for responding to the queries in a timel y manner, within the system, 
either by confirming the data as correct or updating the original entry, and providing the reason 
for the update ( iedata entry  error).At the conclusion of the trial, Gilead will provide the site 
witha read-only archive copy  of the data entered by  that site. This archive must be stored in 
accordance with the records retention requirements outlined in Section 9.1.5.
9.1.7. Investigational Medicinal Product Accountability and Return
Where possible, study  drugshould be destroy ed at the site. At the start of the study , the study  
monitor will evaluate each study  center’s study  drugdisposal procedures and provide appropriate 
instruction for disposal or return of unused study  drugsupplies. If the site has an appr opriate 
standard 
operating p rocedure (SOP) for drug destruction as determined b y Gilead Sciences, the 
site may destroy used (empty or partially  empty) and unused study  drugsupplies as long as 
performed in accordance with the site’s SOP. This can occur onl y afterthe study monitor has 
performed drug accountability  during an on- site monitoring visit . 
A copy of the site’s Study DrugDisposal SOP or written procedure (signed and dated b y the PI 
ordesignee) will be obtained for Gilead site files. If the site does not have acceptable 
procedures in place, arrangements will be made between the siteand Gilead Sciences 
(orGileadSciences’ representative) for return of unused study  drug supplies. 
If study drugis destroyed on site, the investigator must maintain accurate records for all study 
drugsdestroyed. Upon study  completion, copies of the study  drugaccountability  records must be 
filed at the site. Another copy  will be returned to Gilead
.
The study  monitor will review study drug supplies and associated records at periodic intervals.
9.1.8. Inspections
The investigator will make available all source documents and other records for this trial to 
Gilead’s appointed stud y monitors, to IRBs/IECs, or to regulatory  authority or health authorit y 
inspectors.
9.1.9. Protocol Co mpliance
The investigator is responsible for ensuring the study  is conducted in accordance with the 
procedures and evaluations described in this protocol.
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page84 05July20169.2. Sponsor Responsibilities
9.2.1. Protocol Modifications
Protocol modifications, except those intended to redu ce immediate risk to study  subjects, may  be 
made only  by Gilead. The investigator must submit all protocol modifications to the IRB/IECin 
accordance with local requirements and receive documented IRB/IECapproval before 
modifications can be implemented.
9.2.2. S tudy Report and Publications
A clinical study  report (CSR) will be prepared and provided to the regulatory  agency(ies).Gilead 
will ensure that the report meets the standards set out in the I CH Guideline for Structure and
Content of Clinical Study Reports (ICHE3). Note that an abbreviated report may  be prepared in 
certain cases. 
Investigators in this study  may communicate, orally  present, or publish in scientific journals or 
other scholarl y media only after the following conditions have been met:
the results of the study  in their entiret y have been publicly disclosed b y or with the consent of 
Gilead in an abstract, manuscript, or presentation form or the stud y has been completed at all 
study sites for at least 2 years
The investigator will submit to Gilead any proposed publication or presentation alongwith the 
respective scientific journal or presentation forum at least 30 day s before submission of the 
publication or presentation. 
No such communication, presentation, or publication will include Gilead’s c onfidential 
information (see Section 9.1.4).
The investigator will comply  with Gilead’s request to delete references to its confidential 
information (other than the study  results) in any  paper or presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obtain patent protection if 
deemed necessary .
9.3. Joint Investigator/Sponsor Responsibilities
9.3.1. Payment Reporting
Investigators and their study  staff may  be asked to provide services performed under this 
protocol, 
ieattendance at I nvestigator's Meetings.  If requi red under the applicable statutory  and 
regulatory  requirements, Gilead will capture and disclose to Federal and State agencies any  
expenses paid or reimbursed for such services, including an y clinical trial payments, meal, travel 
expenses or reimbursements , consulting fees, and any  other transfer of value.
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page85 05July20169.3.2. Access to Information for Monitoring
In accordance with regulations and guidelines, the study  monitor must have direct access to the 
investigator’s source documentation in order to verify  the accuracy  of the data recorded in the 
CRF/eCRF.
The monitor is responsible for routine review of the CRF/eCRF at regular intervals throughout 
the study to verify adherence to the protocol and the completeness, consistency , and accuracy  of 
the data being entered on them. The monitor should have access to an y subject records needed to 
verify the entries on the CRF/eCRF. The investigator agrees to cooperate with the monitor to 
ensure that an y problems detected through an y type of  monitoring (central, on site) are resolved .
9.3.3. Access to Information for Auditing or Inspections
Representatives of regulatory  authorities or of Gilead may  conduct inspections or audits of the 
clinical study . If the investigator is notified of an inspection by  a regulatory authority  the 
investigator agrees to notify the Gilead medical monitor immediately . The investigator agrees to 
provide to representatives of a regulatory  agency or Gilead access to records, facilities, and 
personnel for the effective conduct of an y inspection or audit.
9.3.4. Study Discont inuation
Both the sponsor and the investigator reserve the right to terminate the stud y at any time. Should 
this be necessary , both parties will arrange discontinuation procedures and notify  the appropriate 
regulatory  authority(ies), IRBs, and IECs. In ter minating the stud y, Gilead and the investigator 
will assure that adequate consideration is given to the protection of the subjects’ interests.
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page86 05July201610. REFERENCES
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, et al. 2010 
Rheumatoid arthritis classification criteria: an American College of 
Rheumatology /European L eague Against Rheumatism collaborative initiative. 
Arthritis Rheum 2010;62 (9):2569-81.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatin ine. Nephron 
1976;16:31-41.
Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College 
of Rheumatology . Preliminary  definition of improvement in rheumatoid arthritis. 
Arthritis Rheum 1995;38 (6):727 -35.
Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the 
prevalence of arthritis and other rheumatic conditions in the United States. Part I . 
Arthritis Rheum 2008;58 (1):15-25.
Lopez-Olivo MA, Siddhanamatha HR, Shea B, Tugwell P, Wells GA, Su arez-Almazor ME. 
Methotrexate for treating rheumatoid arthritis. Cochrane Database S yst Rev 
2014;6:CD000957.
Namour F, Diderichsen PM, Cox E, Vay ssiere B, Van der Aa A, Tasset C, et al. 
Pharmacokinetics and Pharmacokinetic/Pharmacody namic Modeling of Filgotinib 
(GLPG0634), a Selective JAK1 I nhibitor, in Support of Phase IIB Dose Selection. 
Clin Pharmacokinet 2015;54 (8):859-
74.
Prevoo ML , van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL . 
Modified disease activity scores that include twe nty-eight-joint counts. 
Development and validation in a prospective longitudinal study  of patients with 
rheumatoid arthritis. Arthritis Rheum 1995;38 (1):44-8.
Redlich K, Schett G, Steiner G, Hay er S, Wagner EF, Smolen JS. Rheumatoid arthritis therap y 
after tumor necrosis factor and interleukin -1 blockade. Arthritis Rheum 2003;48 
(12):3308-19.
Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 
2008 American College of Rheumatology  recommendations for the use of 
disease-modifying antirheumatic drugs and biologic agents in the treatment of 
rheumatoid arthritis. Arthritis care & research 2012;64 (5):625-39.
The EuroQol Group. EuroQol --a new facility  for the measurement of health- related quality  of 
life. . Health Policy  1990;16 (3):199-208.
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page87 05July2016Zhang W, Bansback N, Boonen A, Young A, Singh A, Anis AH. Validity  of the work 
productivity  and activity  impairment questionnaire --general health version in 
patients with rheumatoid arthritis. Arthritis research & therap y 2010;12 (5):R1 77.
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page88 05July201611. APPENDICES
Appendix 1.Investigator Signature Page
Appendix 2.Study Procedures Table
Appendix 3.Management of Clinical and Laboratory Adverse Events
Appendix 4.Common Terminology Criteria for Adverse Events (CTCAE) v4.03
Appendix 5.Pregnancy Precautions, Definition for Female of Childbearing Potential, and
Contraceptive Methods
Appendix 6.Laboratory Assessment Table
Appendix 7.List of Joints to be Evaluated (66/68 Joint Count)
Appendix 8.The 2010 American College of Rheumatology –European League Against 
Rheumatism Collaborative Initiative Classification Criteria for Rheumatoid 
Arthritis {Aletaha et al 2010} ,
Appendix 9.American College of Rheumatology Response Evaluations/ Preliminary Definition 
of Improvement in Rheumatoid Arthritis {Felson et al 1995}
Appendix 10.Disease Activity Score (DAS28) {Prevoo et al 1995}
Appendix 11.Procedures and Specifications
PPDFilgotinib 
Protocol GS-US-417-0302 Final 
Gilead Sciences, Inc. Amendment 1 
Appendix 1. Investigator Signature Page 
GILEAD SCIENCES, INC. 
333 LAKESIDE DRIVE 
FOSTER CITY, CA 94404, USA 
STUDY ACKNOWLEDGE:MENT 
A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the 
Efficacy and Safety of Filgotinib Administered for 24 weeks in Combination with Conventional 
Disease-modifying Anti-rheumatic Drug(s) (DMARDs) to Subjects with Moderately to Severely 
Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD(s) 
Treatment 
GS-US-417-417-0302, Amendment 1, 05 July 2016 
This protocol has been approved by Gilead Scienc;es~,~In~c::::_·...::T~ h:.:::e~~~~~=~ d::o~cum=::::en~ts::......., 
this approval. 
+eALJZiUA Ht\12\e\ £5. 1 ho 
Name (Printed) 
Author 
INVESTIGATOR STATEMENT 
I have read the protocol, including all appendices, and I agree that it contains alJ necessary 
details for me and my staff to conduct this study as described. I will conduct this study as 
outlined herein and wilJ make a reasonable effort to complete the study within the time 
designated. 
I will provide all study personnel under my supervision copies of the protocol and access to all 
information provided by Gilead Sciences, Inc. I will discuss tllls material with them to ensure 
that they are fully informed about the drugs and the study. 
Principal Investigator N arne (Printed) Signature 
Date Site Number 
CONHDENTIAL Page 89 05 July 2016 
Filgotinib 
Protocol GS-US-41 7-0302 Final 
Gilead Sciences, Inc. Amendment 1 
Appendix 2. Study Procedures Table 
Follow 
EVENT Treatment Period up• 
W24/ Post-
W2 W4 ws W12 W14 W16 W20 ETC Treatment SCl'eening Day 1 b (±3 (±3 (±3 (±3 (±3 (±3 (±5 (±5 Week4 
Study days /weeks (W) (-28 Days) days) days) days) days) days) days) days) days) (± 5 days) 
hlfonned consent X 
Inclusion/exclusion criteria X xd 
Demographics and Baseline disease X characteri stics 
~ 
~ RA Diagnosis and Prior Treatment , Medical e X 
~ history• 
"' , 
< Complete Physical Examination f X X Cl) = ·= ... CD19 connt (for subjects with prior rituxin1ab ... X ... 
" therapy) fJ) 
TB test and Chest X-ray g X 
Serologyh X 
Endocrine: FSH, TSH, and HbAlc X 
CONFIDENTIAL Page 90 05 July 2016 
PPDFilgotinib 
Protocol GS-US-417-0302 
Gilead Sciences , Inc. 
EVENT 
Study days /weeks (W) 
Subject's global assessment i 
~ HAQ-DI and Pain Scale i ... ·; = = 0 F ACIT -Fatigue, SF-36 questionnaire, EQ-5D, ·.:: 
"' WPAI-RA 1 ... = Cl .... 
Healthcare resource utilization questi01maire = ... 
<= andTSQM' = ~ 
... Physician's global assessment ... 
~ ·;; 
Vital signs i 0 ... C:...!l 
~ :il MeastU'ement of weight and Symptom driven s a .. "' physical examination >< ... 
r.J ~ - < 5 12-LeadECG ·;; 
>. -= c:... SJC 66/TJC 68 
CONFIDENTIAL W2 W4 
Sct•eening Dayl b (±3 (±3 
(-28 Days) days) days) 
X X X X 
X X X X 
X X 
X 
X X X X 
X X X X 
X X X 
X 
X X X X 
Page 91 Treatment Period 
ws W12 W14 W16 
(±3 (±3 (±3 (±3 
days) days) days) days) 
X X X X 
X X X X 
X 
X 
X X X X 
X X X X 
X X X X 
X 
X X X X W24/ 
W20 ETC 
(± 5 (±5 
days) days) 
X X 
X X 
X 
X 
X X 
X X 
X 
X 
X X Final 
Amendment 1 
Follow up• 
Post-
Treatment 
Week4 
(± 5 days) 
X X X 
05 July 2016 1 
PPDFilgotinib 
Protocol GS-US-41 7-0302 
Gilead Sciences , Inc. 
EVENT 
Study days /weeks (W) 
Hematology and chemistty k 
Rhemnatoid factor, anti-CCP Ab 
Urinalysis 
Urine Biomarker Sample 1 
Lipid profile (fasting) 
"' .... = "' s 
"' PK blood samples n ~ "' -< 
t Plasma biomarker sample, Senun biomarker s = sample, Blood transcriptome sample, Blood ... 
0 TCRIBCR repertoire sample 0 
.1:> = ;..l 
Pregnancy test P 
SenunCRP 
Viral Monitoring q 
Explorat01y Lab Panel: Leptin, LDL particle, 
Homocystein , Apo A liB, HbAlc r 
Quantitative Ig 
CONFIDENTIAL W2 W4 
Sct•eening Day l b (±3 (±3 
(-28 Days) days) days) 
X X X X 
X 
X X 
X X 
X 
X X 
X X X X X X X X 
X 
X 
Page 92 Treatment Period 
ws W12 W14 W16 
(±3 (±3 (±3 (±3 
days) days) days) days) 
X X X X 
X X 
X X 
X X 
X X X X 
X X X X 
X W24/ 
W20 ETC 
(± 5 (±5 
days) days) 
X X 
X 
X 
X 
X 
X 
X X 
X X 
X 
X 
X Final 
Amendment 1 
Follow up• 
Post-
Treatment 
Week4 
(± 5 days) 
X 
X 
I 
X 
05 July 2016 
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page93 05July2016EVENT Treatment PeriodFollow
Up a
Study days /weeks (W)Screening
(-28 Days)Day 1 bW2 
(± 3 
days)W4 
(± 3 
days)W8 
(± 3 
days)W12 
(± 3 
days)W14 
(± 3 
days)W16 
(± 3 
days)W20 
(± 5 
days)W24/
ET c
(± 5 
days)Post-
Treatment 
Week 4
(± 5 days)
Carotid Artery UltrasoundsX X
AE assessment X X X X X X X X X X X
Review Concomitant Medications X X X X X X X X X X X
Randomization/reassignment XtXu
Study Drug Dispensation vX X X X X X
Review Entry criteria for LTE (if applicable) X
a The follow-up visit will be performed only for subjects discontinuing prematurely from the study and for those completing week 24, but n ot entering the LTE.
bSubject will begin medication on Day 1, following baseline assessments and randomization.
cEarly Ter mination Visit to be performed if subject discontinues before Week 24.
d Eligibility criteria check based on the laboratory results from the Screening visit, TJC/SJC at screening and day 1, and for female subjects of childbearing potential, the urine 
pregnancy test is performed at Day 1.
e Medical History includes smoking status, average weekly alcohol consumption, family history of coronary heart disease (CHD) a ny other chronic medical conditions or prior 
surgeries.
fAt Screening and Week 24 (or at ET), a compl ete physical examination , including weight should be performed. Symptom -directed exams should be performed at all other 
visits. Height will be measured at Screening only.
gChest X-rayfor TBshould be performed if not performed in the previous 3 months, and results are available at the site. 
h Hepatitis B surface Ag and core Ab, reflex Hep B DNA, Hepatitis C Ab, reflex HCV RNA, HIV 1 and 2 at Screening.
i  
jVital signs includeheart rate, respiratory rate, blood pressure (systolic and diastolic) and temperature.
k Refer to list provided in Laboratory assessment table ( Appendix 6).Hemoglobin A1c and TSH will be measured at Screening only. 
lUrine biomarker sample collected on Day 1 and Week 24/ET only. 
m   
n One blood sample will be collected for analysis of filgotinib and its active meta bolite (GS -829845 ) in plasma. The PK sample at Week 4 should be collected at least 
30minutes post study drug dose. PK samples at Week 12 and Week 24 visit should be collected prior to study drug dose (within 2 hours prior to dosing) at the visit. PK 
samples at week 16 or ET can be collected anytime during the visit.  
PPD
PPD
PPD
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page94 05July2016 
oDetails of biomark er collection are outlined in lab manual.
pFor female subjects of childbearing potential only. To be performed on serum sampleat Screening and on urine samples for other visits. For female subjects entering the LTE, 
at the Week 24 visit, pregnancy test should be performed on serum. f any pregnancy test is positive, study drug should be immediately interrupted and the subject should 
come to the site for serum pregnancy test.
q Viral monitoring for HBV or HCV as applicable (See exclusion crite ria Section 4.3)
rSitesparticipating in the Coratic Artery Ultrasound study: Leptin, LDL particle, Homocystein, Apo A1/B, HbA1c will be performed at Screening and Week 24.
s Carotid artery ultrasounds will be performed w hen availableat selected sites, at Da y 1 (+ 7 window) and Week 24 (± 7 day window).
tUpon qualification for the study .
uAt Week 14, subjects who failed to achieve both a TJC and SJC improvement of ≥20% will be treated as inadequate responders .
vDispensation of study drugs according to IWRS man ual.
PPD
Filgotinib
Protocol GS -US-417-0302 Final
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page95 05July2016Appendix 3. Management of Clinical and Laboratory Adverse Events
Grade I 
L_ ____ G_r_a_de-2----~~· ~ ----- G-r-a-de-3----~~ Ll -------- G -r-a-de-4--------~ 
! 
May continue Repeat lab to 
dosing at the confirm toxicity 
discretion of the grade 
investigator 
If confirmed and possibly and/or probably related to 
investigational medicina l products: 
I. Withhold investigational medicina l products until 
:S Grade 2 
2. Restart all investieational medicinal oroducts at full dose 
1 
If Grade 3 or 4 recurrence that is confirmed and possibly or 
probably related to investigat ional medicinal products, 
discontinue all investigational medicinal products dosing 
oermanentlv 1 Repeat lab to 
confirm toxicity 
grade 
1 
lfc onfirmed and unrelated to 
estigational medicina l inv 
pro 
the ducts, dosing may continue at 
discretion of the investigator If confirmed and 
possibly or probably 
---+ related to 
investigational 
medicinal products , 
discontinue 
investigational 
medicinal products 
dosing permanent ly 
and follow at 
periodic intervals at 
least weekly until a 
return to baseline or 
is otherwise 
explained 
If Grade 3 or 4 recurrence that is considered unrelated to 
investigationa l medicina l products, continue all 
investigational medicina l products at the same dose at the 
discretion of the investigator 
Filgotinib
Protocol GS –US-417-0302 Final 
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page96 05July2016Appendix 4. Common Terminology Criteria for Adverse Events (CTCAE) v4.03
CTCAE v4.03 can be accessed from the below link:
http://www.hrc.govt.nz/sites/default/files/CTCAE%20manual%20 -%20DMCC.pdf
The only modification to the CTCAE criteria is the addition of a Grade 1 upper respiratory  
infection as follows:
CTCAE 
v4.0 Term Grade 1 Grade 2 Grade 3
Grade 4 Grade5CTCAE v4.03 
AE Term 
Definition
Upper 
respiratory 
infectionMild 
symptoms; 
symptomatic 
relief (eg, 
cough 
suppressant, 
decongestant)Moderate 
symptoms; 
oral 
intervention 
indicated 
(eg,antibiotic, 
antifungal, 
antiviral)IV antibiotic, 
antifungal, or 
antiviral 
intervention
indicated; 
radiologic, 
endoscopic, or 
operative 
intervention 
indicatedLife-
threatening 
consequences; 
urgent 
intervention 
indicatedDeath A disorder 
characterized by 
an infectious 
process involving 
the upper 
respiratory tract 
(nose,paranasal 
sinuses, pha rynx, 
larynx, or 
trachea).
Filgotinib
Protocol GS –US-417-0302 Final 
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page97 05July2016Appendix 5. Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Methods
The administration of filgotinib in embry o-fetal animal development studies resulted in 
decreased numbers of viable rat fetuses, increased resorptions, and visceral and skeletal 
malformations.  Similar effects were noted in the rabbit. A safet y margin rela tive to human 
exposure has not been identified.  Pregnancy  is contraindicated during use of filgotininb.
For participation in this study , all subjects of childbearing potential must agree to the use of 
highly effective contraception as outlined below.
1)Definitions
a)Definition of Childbearing Potential
For the purposes of this study , a female- born subject is considered of childbearing potential 
following the initiation of pubert y (Tanner stage 2) until becoming post -menopausal, unless 
permanentl y sterile or wi th medically  documented ovarian failure.  
Women are considered to be in a postmenopausal state when they  are >54years of age with 
cessation of previously  occurring menses for > 12 months without an alternative cause. In 
addition, women of an y age with amenorrhea >12 months may  also be considered 
postmenopausal if their FSH level is in the postmenopausal range at Screening and they  are not 
using hormonal contraception or hormona l replacement therap y.   `
Permanent sterilization includes hy sterectomy , bilateral oophorectom y, or bilateral 
salpingectomy in a female subject of an y age.
b)Definition of Male Fertility
For the purposes of this study , a male-born subject is considered fertile after the initiation of 
puberty unless permanently  sterile by bilateral orchidectomy  or has medical documentation of 
permanent male infertility.
2)Contraception for Female Subjects
a)Study Drug Effects on Pregnancy and Hormonal Contraception
Filgotinib is contraindicated in pregnancy  as there is a possibility  of human 
teratogenicit y/fetotoxicity  in early pregnancy based on non- clinical data. A dedicated stud y 
assessing the impact of filgotinib on the efficacy  of hormonally -based contraceptives 
(withovulation inhibition as mechanism of action) has not y et been performed to fully  verify the 
absence of an y clinically significant interaction between filgotinib and oral contraceptives.  
However, clinicall y relevant drug- drug interactions between hormonally -based contraceptives 
and filgotinib or its active metabolite GS -829845 are not expected. In vitro studies in HepaRG 
cells using reference substrates indicate that filgotinib and GS -829845 do not induce CYP1A2, 
Filgotinib
Protocol GS –US-417-0302 Final 
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page98 05July2016CYP2B6, or CYP3A4, enzy mes involved in metabolism of common hormonal contraceptives. 
Preliminary  results using primary  human hepatocy tes also confirmed that filgotinib and 
GS-829845 did not induce mRNA expression of CYP1A2, CYP2B6, or CYP3A4. The lack of 
induction potential of filgotinib and GS -829845 on CYP3A4 was further confirmed in a clinical 
drug-drug interaction study , where multiple dose administration of 200 mg filgotinib did not 
affect the pharmacokinetics of midazolam (a prototy pical in vivo probe CYP3A4 substrate). 
Additionally , clinically relevant inhibition of CYPs or UGTs during filgotinib treatment is 
unlikely, based on in vitro data.
Based on the totality  of the in vitro and clinical data, clinically  relevant drug interactions 
between filgotinib or GS -829845 with hormonal contraceptives are not expected. For female 
subjects, hormonal contraceptives will be permitted as a form of contraception when used in 
conjunction with a barrier method (preferably male condom) . For male subjects, male condom 
should be used; for their female partners of childbearing potential ,an accepted contraceptive 
methodshould also be considered . Details are outlined below.
Please refer to the latest version of the filgotinib investigator’s brochure for additional 
information.
b)Contraception for Female Subjects of Child bearing Potential
The inclusion of female subjects of childbearing potential requires the use of highl y effective 
contraceptive measures.  Women must have a negative serum pregnancy  test at Screening and a 
negative urine pregnancy test on the Baseline/Day 1 visit prior to randomization.  Pregnancy  
tests will be performed at monthly  intervals thereafter.  In the event of a delay ed menstrual 
period (>one month between menstruations), a pregnancy  test must be performed to rule out 
pregnancy .  This is true even for women of childbearing potential with infrequent or irregular 
periods. 
Female subjects must agree to useone of the following methods from Sc reening until 
35days following the last dose of study  drug. 
Complete abstinence from intercourse of reproductive potential.  Abstinence is an acceptable 
method of contraception only  when it is in line with the subject’s preferred and usual 
lifestyle.
Or
Consistent and correct use of 1 of the following methods of birth control listed below. 
Intrauterine device (IUD) with a failure rate of <1% per year
Tubal sterilization
Essure micro- insert system (provided confirmation of success 3 months after procedure )
Filgotinib
Protocol GS –US-417-0302 Final 
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page99 05July2016Vasectom y in the male partner (provided that the partner is the sole sexual partner and 
had confirmation of surgical success at least 3 months after procedure , with 
documentation of sperm- free ejaculate )
These above described methods are considered preferred methods of highly effective 
contraception in this protocol.
Female subjects who wish to use a hormonall y based method must agree to use itin conjunction 
with a barrier method (used either b y the female subject or b y her male partner) .  Female s
ubjects 
who utilize a hormonal contraceptive as one of their birth control methods must have
consistently used the same method for at least three months prior to study  dosing.Hormonall y-
based contraceptives and barrier methods permitted for use in this protocol are as follows:
Hormonal methods ( subject must agree to use with a 
barrier method, preferably , with a male 
condom)
Oral contraceptives (either combined estrogen/progestin or progesterone only )
Injectable progesterone
Implants of levonorgestrel
Transdermal contraceptive patch
Contraceptive vaginal ring
Barrier methods (subject must agree to use with a hormonal method)
Male or female condom, with or without spermicide
Diaphragm with spermicide
Cervical cap with spermicide
Sponge with spermicide
All female subjects must also agree to refrain from egg donation and in vitro fertilization 
during study participation and for at least 35days after the last study  drug dose .
3) Contraception for Male Subjects
It is theoreticall y possible that a relevant s ystemic concentration may  be achieved in a female 
partner from exposure to the male subject’s seminal fluid.  Therefore, male subjects with female 
partners of childbearing potential must agree touse condoms during study  participation and for 
90 days after the last study  drug dose .  Female partners of male stud y subjects should consider 
using one of the above methods of contraception as well . Male subjects must also agree torefrain 
from sperm donation during treatment and until at least 90 days after the end of dosing.
Filgotinib
Protocol GS –US-417-0302 Final 
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page100 05July20164) Unacceptable Birth Control Methods
Birth control methods that are unacceptable include periodic abstinence (e,g, calendar, ovulation, 
symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides onl y, and 
lactational ame norrhea method (LAM).  Female condom and male condom should not be used 
together.
5) Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify  the investigator if they  become pregnant at any  time during 
the study, or if they  become pregnant within 35 days of last study  drug dose.  Subjects who 
become pregnant or who suspect that they  are pregnant during the stud y must report the 
information to the investigator and discontinue study  drug immediatel y. Subjects whose partner 
has become pregnant or suspects she is pregnant during the stud y are toreport the information to 
the investigator.
Instructions for reporting pregnancy , partner pregnancy , and pregnancy  outcome are outlined in 
Section7.7.2.1.
Filgotinib
Protocol GS –US-417-0302 Final 
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page101 05July2016Appendix 6. Laboratory Assessment Table
Hematology Chemistry Urinalysis Other
Hematocrit
Hemoglobin
Platelet count
Red blood cell (RBC) 
count
Red blood cell indices
White blood cell (WBC) 
count
Differentials (absolute 
and percentage), 
including:
Leucocytes
Monocytes
Neutrophils
Eosinophils
Basophils
Mean corpuscular 
volume (MCV)Alkaline phosphatase
Aspartate aminotransferase 
(AST)
Alanine aminotransferase 
(ALT)
Gamma-glutamyl 
transpeptidase (GGT)
Total bilirubin
Direct and indirect bilirubin
Total protein
Albumin
Bicarbonate
Blood urea nitrogen (BUN)
Calcium
Chloride
CPK
Serum creatinine
Glucose
Phosphorus
Magnesium
Potassium
Sodium
Amylase
Lipase 
Uric acid
Lipid profile: 
Triglycerides
Cholesterol and its 
subfractions (high -density 
lipoprotein [HDL] and low-
density lipoprotein [LDL])Appearance
Blood
Color
Glucose
Specific gravity
Nitrites
Leukocyte esterase
pH
Protein
Urobilinogen
Reflex to microscopic 
urinalysis if dipstick result 
is abnormal.Urine drug screen for:
Amphetamines
Cocaine
Methadone
Opiates
C-reactive protein (hsCRP)
Rheumatoid factor and anti 
cyclic citrullinated peptide 
antibody (RF/Anti-CCP)
QuantiFERON -TB GOLD 
QuantitativeIg subclasses at 
Screeningand Week 24 
In the carotic imaging study 
at selected sites and where 
available at Screening and 
Week 24: 
Leptin 
LDL particle
Homocystein
Apo A1/B
HbA1c
Endocrine (At 
Screening Only) Serology Pregnancy
Hemoglobin A1c
TSH
FSHHepatitis BsAg and core 
Ab (if positive core Ab, 
then reflex Hep B DNA)
Hepatitis C Ab (if positive 
then reflex HCV RNA)
HIVIn females of childbearing 
potential:
Serum β-hCG (Screening 
and if positive urine β -
hCG)
Urine β-hCG (all other 
visits)
Filgotinib
Protocol GS –US-417-0302 Final 
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page102 05July2016Appendix 7. List of Joints to be Evaluated ( 66/68 Joint Count )
An overview of the joints assessed is provided below (left and right):
Temporomandibular 
Sternoclavicular 
Acromioclavicular 
Shoulder 
Elbow
Wrist
Metacarpophalangeal: first, second, third, fourth, fifth 
Proximal interphalangeal: first, second, third, fourth, fifth
Distal interphalangeal: second, third, fourth, fifth
Hip2# 
Knee 
Ankle 
Tarsus 
Metatarsophalangeal: first, second, third, fourth, fifth 
Proximal interphalangeal (toe) : first, second, third, fourth, fifth
Replaced (or otherwise not assessable) joints should be documented at screening and omitted 
from further evaluation during the stud y.
                                                
2Assessed for tenderness only
Filgotinib
Protocol GS –US-417-0302 Final 
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page103 05July2016Appendix 8. The 2010 American College of Rheumatology –European League
Against Rheumatism Collaborative Initiative Classification Criteria 
for Rheumatoid Arthritis {Aletaha et al 2010},
Target population (Who should be tested?): Patients who have at
 least 1 joint with 
definite clinical synovitis (swelling)awith the synovitis not better explained by 
another diseaseb
Classification criteria for RA (score- based algorithm : add score of categories A -D;
a score of ≥ 6/10 is needed for classification of a patient as having definite RA)c
A. Joint involvementd
1 large jointe0
2-10 large joints 1
1-3 small joints (w ith or without involvement of large joints)f2
4-10 small joints (with or w ithout involvement of large joints) 3
>10 joints (at least 1 small joint)g5
B. Serology (at least 1 test result is needed for classification)h
Negative RF andnegative ACPA 0
Low-positive RF orlow-positive ACPA 2
High-positive RF orhigh-positive ACPA 3
C. Acute-phase reactants (at least 1 test result is needed for classification)i
Normal CRP andnormal ESR 0
Abnormal CRP or abnormal ESR 1
D. Duration of symptomsj
<6 weeks 0
≥6 weeks 1
a The criteria are aimed at classification of newly presenting patients. In addition, patients with erosive disease typical of 
rheumatoid arthritis (RA) with a history compatible with prior fulfillment of the 2010 criteria should be classified as havin g 
RA. Patients with longstanding disease, including those whose disease is inactive (with or without treatment) who, bas ed on 
retrospectively available data, have previously fulfilled the 2010 criteria should be classified as having RA.
bDifferential diagnoses vary among patients with different presentations, but may include conditions such as systemic lupus 
erythematosu s, psoriatic arthritis, and gout. If it is unclear about the relevant differential diagnoses to consider, an expert 
rheumatologist should be consulted.
c Although patients with a score of <6/10 are not classifiable as having RA, their status can be reasses sed and the criteria 
might be fulfilled cumulatively over time.
dJoint involvement refers to any swollenortenderjoint on examination, which may be confirmed by imaging evidence of 
synovitis. Distal interphalangeal joints, first carpometacarpal joints, and first metatarsophalangeal joints are excluded from
assessment . Categories of joint distribution are classified according to the location and number of involved joints, with 
placement into the highest category possible based on the pattern of joint invo lvement.
e "Large joints" refers to shoulders, elbows, hips, knees, and ankles.
f "Small joints" refers to the metacarpophalangeal joints, proximal interphalangeal joints, second through 
fifthmetatarsophalangeal joints, thumb interphalangeal joints, and wrists.
gIn this category, at least 1 of the involved joints must be a small joint; the other joints can include any combination of la rge 
and additional small joints, as well as other joints not specifically listed elsewhere (eg, temporomandibular, 
acromioclavicular, sternoclavicular).
Filgotinib
Protocol GS –US-417-0302 Final 
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page104 05July2016h Negative refers to IU values that are less than or equal to the upper limit of normal (ULN) for the laboratory and assay; 
low-positive refers to IU values that are higher than the ULN but ≤3 times the ULN for the laboratory and assay; 
high-positive refers to IU values that are >3 times the ULN for the laboratory and assay. Where rheumatoid factor (RF) 
information is only available as positive or negative, a positive result should be scored as low -positive for RF. 
ACPA=anti-citrullinated protein antibody.
i Normal/abnormal is determined by local laboratory standards. CRP = C-reactive protein; ESR = erythrocyte sedimentation 
rate.
jDuration of symptoms refers to patient self -
report of the duration of signs or symptoms of syn ovitis (e.g., pain, swelling, 
tenderness) of joints that are clinically involved at the time of assessment, regardless of treatment status.
Filgotinib
Protocol GS –US-417-0302 Final 
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page105 05July2016Appendix 9. American College of Rheumatology Response Evaluations/ 
Preliminary Definition of Improvement in Rheumatoid Arthritis 
{Felson et al 1995 }
ACR 20 Required ≥ 20% improvement in tender joint count ,AND
≥ 20% improvement in swollen joint count, AND
≥ 20% improvement in at least 3 of the following 5 items:
Patientpain assessment
Patient global assessment of disease activity
Physician global assessment of disease activity
Patient assessment of physical function (HAQ -DI) 
Acute-phase reactant (CRP)
The following lists the disease activity measure followed by the me thod of assessment
1.Tender joint count
ACR tender joint count is an assessment of 68. The joint count should be done by  scoring several 
different aspects of tenderness, as assessed b y pressure and joint manipulation on physical 
examination. The informati on on various ty pes of tenderness should then be collapsed into a 
single tender -versus-nontender dichotom y.
2.Swollen joint count
ACR swollen joint count is an assessment of 66. Joints are classified as either swollen or not 
swollen.
3.Patient’s 
assessment of pain
The pain score from the HAQ -DI will be used to calculate ACR response.
Filgotinib
Protocol GS –US-417-0302 Final 
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page106 05July20164.Patient’s global assessment of disease activity
A horizontal, visual analog scale will be used to provide the patient’s overall assessment of how 
the arthritis is doing.
Place a mark on the line below to indicate how you assess your current rheumatoid
arthritis disease activity:
   No arthritis Severearthritis
5. Physician’s global assessment of disease activity
A horizontal visual analog scale will be used to measure the phy sician’s assessment of the 
patient’s current disease activity .
Place a mark on the line below to indicate RA disease activity  (independent of the subject’s 
self-assessment):
No Disease Activity                                                                                 Maximum Disease Activity
6.Patient’s assessment of physical function
The HAQ -DI will be used to provide a patient’s self -assessment of phy sical function.
7.Acute-phase reactant value
C
-reactive protein level as measured at the central laboratory
Filgotinib
Protocol GS –US-417-0302 Final 
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page107 05July2016Appendix 10. Disease Activity Score (DAS28) { Prevoo et al 1995 }
Assessments of RA in patients by  the Disease Activity  Score (modified to include the 28 joint 
counts according to Smolen* 1995) will be conducted at the measured timepoints . The DAS28 
consists of a composite score of the following variables: tender joint count, swollen joint count, 
CRP, and patient global score. The following equation will be used to calculate the DAS28 -CRP
DAS28-CRP 0.56 √TJC28 0.28√SJC280.36ln(CRP 1) 0.014(patients global VAS) 
0.96
TJC28 = number of joints tender out of 28
SJC28 = number of joints swollen out of 28
CRP = C-reactive protein
Patient global VAS = patient global assessment as defined in  
Appendix 9
Filgotinib
Protocol GS –US-417-0302 Final 
Gilead Sciences, Inc. Amendment 1
CONFIDENTIAL Page108 05July2016Appendix 11. Procedures and Specifications 
Complete Physical Examination
A complete ph ysical examination should include source documentation of general appearance, 
and the following bod y systems: Head, neck and thy roid; eyes, ears, nose, throat, mouth and 
tongue; chest (excluding breasts); respiratory; cardiovascular; l ymph nodes, abdomen; skin, hair, 
nails; musculo skeletal; neurological (must be performed at Screening). 
Blood Pressure
Assessment of vital signs will include measurement of resting blood pressure, pulse, respiratory  
rate, and temperature.
Blood pressure will be measured using the following standardized process:
Subject should 
be resting for 5 minutes with feet flat on the floor and measurement arm 
supported so that the midpoint of the manometer cuff is at heart level;
Use a mercury  sphygmomanometer or automatic blood pressure device with a n appropriately  
sized cuff with the bladder centered over the brachial artery ;
Measure and record the blood pressure to the nearest 2 mmHg mark on the manometer or to 
the nearest whole number on an automatic device.
Creatinine Clearance 
Creatinine clearan ce is calculated b y the Cockcroft -Gault equation {Cockcroft et al 1976 }using 
actual bod y weight (BW). 
Male: CLcr(mL/min) =[140
-age (years)] BW(kg)
72Scr
Female: CLcr(mL/min) =[140-age (years)] BW(kg) 0.85
72Scr
Scr= serum creatinine (mg/dL)
12-Lead ECG
Subjects should be resting in a supine position for 5minutes prior to making a recording.
The investigator (or qualified designee) should review the ECG traces recorded in real time for 
clinically significant abnormalities.  On treatment ECGs should be compared to the subject’s 
Screening 
ECGas part of routine safet y monitoring.  